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ABSTRACT 
Breast cancer is the second leading cause of cancer related deaths in 
women. Advanced breast cancer can metastasize to the lungs, liver, bones and 
brain becoming fatal conditions for many patients. There is a dire need for 
metastasis preventing medications, however the process required for a 
medication to become FDA approved for clinical use is long and arduous. 
Studies have found promising benefits for breast cancer patients given 
ToradolTM, or racemic ketorolac, as an NSAID during resection surgery. 
However, long-term use of racemic ketorolac is not recommended. Currently 
FDA-approved for use in the racemic form, ketorolac has the potential to become 
a valuable off-label drug for cancer patients, and if given as a single enantiomer, 
may not cause toxic effects. 
vii 
 
Recent work on ovarian cancer cell lines has shown (R)-ketorolac to have 
an effect on invasion and migration abilities via interaction with small Rho-
GTPases. We hypothesized that (R)-ketorolac would likewise have the ability to 
inhibit breast cancer invasion and migration by binding to Cdc42, Rac1 and 
RhoA. 
The activity of racemic ketorolac and its enantiomers, (S)-ketorolac and 
(R)-ketorolac was studied in both in vivo and in vitro settings. In breast cancer 
cell lines it was shown that ketorolac does not affect the viability of cells, but does 
inhibit colony formation and migration. In MMTV-PyMT mouse models, ketorolac 
treatment does not appear to have toxic effects on the organism, and may 
prevent early mammary gland tumor growth and, in older mice, metastasis. 
These studies suggest that the (R)- enantiomer of ketorolac may be useful in 
preventing tumor growth and metastasis without imparting significant toxicities. 
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1. INTRODUCTION 
1.1 Breast Cancer Prevalence  
Breast cancer is the second most commonly diagnosed cancer in women 
(1). Although it is most often diagnosed in postmenopausal women, breast 
cancer affects individuals of both sexes and all ages. In 2015, an estimated 
234,190 new cases will be documented and 40,730 individuals will die from 
breast cancer (1). The latest statistics from the American Cancer Society show a 
decline in the total number of breast cancer related deaths over recent years, but 
breast cancer is still the second leading cause of cancer related deaths in women 
after lung cancer (1). 
Risk for developing breast cancer is increased by a variety of factors 
including genetic mutations, lifestyle habits and non-modifiable medical 
conditions and treatments (1). A conscious effort can be made to decrease risk 
but ultimately avoiding breast cancer is not an exact science. Modern medicine 
has enabled us to eradicate breast cancer in a fraction of women but there is still 
need for more effective treatments. Chemotherapy options with less severe side 
effects for the patient are necessary, as well as the availability of safe chronic 
medications for preventing metastasis or relapse. 
Breast cancer is a heterogeneous disease that varies between individuals. 
Various factors affect the severity as well as the treatability of the disease. For 
example receptor status is a characteristic used to selected targeted drugs. Cells 
that overexpress estrogen receptors (ER) bind estrogen hormones which 
promote cell growth. ER-positive/PR-positive (ER+/PR+) cancer is treatable with 
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hormone therapy, such as Tamoxifen as discussed below (reviewed (2)). 
Tamoxifen treated ER+ patients experience reductions in the risk of recurrence 
and mortality (reviewed (3)). However, ER-negative (ER-) cancer does not 
benefit by this mode of treatment, as its proliferation is due to other factors (4).  
Patients whose cells are negative for ER, PR and HER2 are classified as 
having triple negative breast cancer (TNBC). TNBC is more difficult to treat, as 
the cells lack traditional specific receptor targets (5). Patients exhibiting TNBC 
have more aggressive tumors and a greater chance of recurrence and worse 
prognosis in the first four years after diagnosis, than patients whose cells are 
ER+, PR+ or HER2-positive (HER2+) (5,6).  
Treatments for breast cancer patients generally begin with tumor and 
lymph node biopsies to determine the extent of disease and characteristics of the 
tumor (7). Most patients then undergo adjuvant therapy followed by surgical 
procedures to remove tumors and affected lymph nodes. Surgery may be 
preceded by chemotherapy to reduce the amount of tissue removed (7). 
Afterwards, patients receive radiation therapy, chemotherapy or hormone therapy 
to ablate remaining cancer cells (8). The types of drugs used for treatment vary 
depending on the receptor status of cells, stage of cancer progression, and the 
degree of metastasis (8,9).  
Current goals in breast cancer research are to decrease the prevalence of 
breast cancer by improving early detection, increasing the effectiveness of 
treatments and decreasing relapse. 
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1.2 Breast Cancer Treatment Targets and Drugs 
Breast cancer drugs currently on the market generally work in one of two 
ways: by interfering with cytoskeleton function, which is essential to cell growth 
and division or by blocking the availability of growth hormones (e.g. estrogen) to 
the cell. Breast cancer drugs can take advantage of these known targets to 
specifically interrupt a cancer cell’s growth and proliferation.  
Overexpression of the HER2/neu (human epidermal growth factor 
receptor 2) gene is found in about 30% of breast tumors (10). Excess HER2 is 
associated with malignancy and decreased survival rates in breast cancer 
patients (reviewed (11,12)). HER2 is involved in regulating cell growth and 
differentiation signaling pathways, and overexpression of HER2 protein leads to 
uncontrolled cell growth (11,13). The HER2 gene encodes a cell surface 
glycoprotein which has tyrosine kinase activity (14,15). Tyrosine kinases 
phosphorylate proteins, which activate phosphatidyl inositol 3-
phosphokinase/protein kinase B (PI3K/Akt) signaling pathways (reviewed (16)). 
The PI3K/Akt signaling pathway controls normal cellular activities that are 
inappropriately balanced in tumors such as cellular proliferation and migration 
(16,17). Increased tyrosine kinase activity is implicated in a number of different 
cancers, including breast cancer (16,17). In breast cancer, HER2 gene 
amplification is associated with more aggressive tumors, greater recurrence rates 
and increased mortality (18–21).  
Patients with HER2/neu-positive cells generally receive treatment with a 
monoclonal antibody called Trastuzumab (Herceptin) (3,5,13,22). Trastuzumab 
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(Herceptin) binds to the human epidermal growth factor receptor 2 
(HER2/neu/erbB-2) and inhibits receptor dimerization and activation of the 
PI3K/Akt pathway (13,23–25). This drug has become a recognized standard 
treatment for HER2 positive (HER2+) breast cancer patients, and is usually used 
in combination with, or after chemotherapy (13,24,26). Much like ER+ breast 
cancer, HER2+ cancer can be more specifically targeted using Trastuzumab 
(5,11). 
Another class of anti-cancer drugs useful in treating breast cancer work by 
blocking estrogen interaction with the cell, either by competing for estrogen 
receptors or preventing conversion of androgen to estrogen, as with Letrozole 
(commercially known as Femara) (27). Tamoxifen, a commonly used estrogen 
receptor antagonist, can be used long term in postmenopausal patients as a 
tumoristatic drug (2). This drug only works in estrogen receptor positive (ER+) 
breast cancers, so it is not effective for all cases of breast cancer(2). In ER+ 
breast cancer cells, estrogen binds to the estrogen receptor, activating a cascade 
of events that enable the cell to grow. When Tamoxifen is administered, it is 
metabolized by the liver into active metabolites that have a great affinity for the 
estrogen receptor (28). The active metabolites compete with estrogen for 
receptor binding, preventing estrogen mediated gene transcription and cancer 
cell growth (28).  
Endocrine therapies, like Tamoxifen, are often used to treat individuals 
with early stage or metastatic breast cancer, as these drugs affect cells all over 
the body (7). Because these drugs affect all cells, they can create adverse side 
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effects. For example, Tamoxifen has been shown to induce liver cancer in rats 
and increase the incidence of other cancers in humans (29,30). Treatment with 
Tamoxifen for breast cancer induces estrogen-like effects on the uterus and is 
linked to an increased risk for uterine cancer due to the drug's agonistic effect on 
G-protein coupled estrogen receptors (GPER) (31–33).  
The lack of targetable receptors in TNBC cells creates a unique challenge 
for cancer drug development. Current work on targeted therapies for TNBC 
employ PARP (poly ADP-ribose polymerase) inhibitors (7). PARP is an enzyme 
that repairs damaged DNA. Inhibiting PARP activity prevents cancer cells from 
repairing damaged DNA causing cells to undergo apoptosis and die instead of 
proliferating.  
Paclitaxel, a Food and Drug Administration (FDA) approved drug 
commercially known as Taxol, is used to treat ovarian, breast, lung, head and 
neck cancers (34). Taxol belongs to a group of agents called taxanes, which 
include doclitaxel and paclitaxel. These agents do not target specific receptors, 
but instead stabilize microtubule filaments in the guanosine diphosphate (GDP) 
state preventing microtubules from disassembling, and inhibiting complete 
mitosis which results in apoptosis of the cell (35).  
The problem with all of these treatments is that they are not absolutely 
cancer cell-specific. Many anti-cancer drugs affect healthy cells as well as the 
cancer cell targets, which leads to undesirable side effects for the patient. 
Additionally, due to the various manifestations of breast cancer, a treatment that 
works for one patient may work only partially or not at all in another patient. 
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Cancer drug resistance is a common problem (reviewed (36–38)). When a 
cancer patient experiences relapse, the same drugs that lead to remission in 
previous treatments may no longer be as effective in subsequent tumors. The 
cancerous patient cells have developed resistance against drugs that kill cancer 
in one specific way, e.g. microtubule growth inhibition. The survival rate of 
relapsed patients is low, and finding anti-cancer treatments that have different 
mechanisms of action than their previous treatment is important. Overcoming 
resistance by discovering new targets and discovering new cancer treatments is 
important in cancer drug discovery.  
In recent years, there has been a developing trend towards individualized 
cancer treatment plans. After initial breast cancer diagnosis, tests are conducted 
to determine the stage of cancer as well as its specific characteristics (7). Biopsy 
samples can be used to determine whether the cancer has specific receptors to 
serve as drug targets. This approach is still only as powerful as the knowledge of 
modified pathways involved in cancer, and drugs available for targeting said 
modifications. New targets are in development. Increasing the number of drugs 
available will allow for more efficient treatments and greater survival rates of 
cancer patients.  
1.3 Drug Repurposing 
 A large area of cancer research is dedicated to the development of new 
drugs to modify and change cellular pathways in cancer cells. Nonetheless, even 
the most effective treatment against cancer cells must be verified in multiple cell 
lines, tested in in vivo models, and undergo animal and human testing for safety. 
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Finally, it must meet strict requirements set by the FDA for use in humans. The 
process required to verify that new compounds are safe and effective is long and 
complicated. Synthesis, biological testing, and pharmacological screening of new 
compounds can take 5-8 years, after which, compounds must still undergo a 
three stage process in order to be deemed safe, possibly adding on another eight 
years before being available for clinical use (39). “Fast forwarding” through any 
step of this process can cut years off of the time needed for new 
chemotherapeutics to be put into routine use. Repurposing previously FDA 
approved drugs for use in cancer treatment is one way to expedite this process. 
FDA approved drugs have already been evaluated for human use. The 
main concern with unconventional use of a drug is using it in concentrations that 
will not cause long lasting harm to the patient, as some treatment regimens may 
require dosages far above the pre-determined safe concentration. According to 
MediLexicon, there are 148 FDA approved drugs available for cancer therapy 
(27). Many of these drugs are designed for very specific cancers and several, 
such as the non-steroidal anti-inflammatory drugs (NSAIDs), are used for treating 
pain associated with cancer.  
1.4 Ketorolac 
Of particular interest is ketorolac tromethamine, marketed as ToradolTM or 
AcularTM. Ketorolac is an FDA-approved NSAID used for treating pain and 
inflammation (40,41). In a clinical setting, this drug is administered as a racemic 
mixture of (R)- and (S)- enantiomers via an initial intravenous (IV) or 
intramuscular (IM) route, then continued orally for no more than five days (42). 
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Ketorolac is contraindicated for long-term use due to its association with 
increased gastrointestinal ulcers, bleeding, and perforation as well as liver and 
renal failure (42). On the other hand, short-term administration of ketorolac has 
demonstrated significant beneficial effects for patients over alternative post- or 
peri-operatively administered pain medications. Recent data have shown that 
when ketorolac is administered perioperatively, breast cancer patients are less 
likely to experience an early relapse and there is an increase in survival after 
surgery (43). Evidence has also shown that perioperative ketorolac 
administration is correlated with improved survival in lung, and ovarian cancer 
patients (44,45). 
In a 2010 study, Forget et al. conducted studies comparing perioperative 
analgesics and anesthetics given to Belgian women who received mastectomies 
from a single surgeon. In these studies, women who had received ketorolac had 
superior disease free survival rates in the first few years after surgery, with the 
greatest differences observed during the 9-18 months after surgery (46). These 
studies were further analyzed by Retsky et al. who hypothesized that ketorolac 
reduces systemic inflammation and angiogenesis, interfering with the metastatic 
ability of circulating tumor cells (43,47). Without a suitable host environment, 
these circulating cells die off. Of note, Retsky et al. proposed that ketorolac could 
be of benefit to TNBC patients regardless of the current lack of targeted therapy 
for TNBC cells (43,47). 
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1.5 Potential Mechanisms of Action of Ketorolac in Breast Cancer Patients 
Although given clinically as a racemic mixture, ketorolac’s two 
enantiomers have differing functions. The S- enantiomer of ketorolac is a known 
cyclooxygenase (COX) inhibitor and useful for managing pain and inflammation 
(48,49). The R-enantiomer, originally thought to be inert, inhibits actin 
cytoskeleton regulators such as Rac1 and Cdc42 GTPases and relieves pain 
independent of COX inhibition (40,50,51). 
(S)-ketorolac inhibits COX enzymes and, consequently, is primarily 
responsible for the ulcerogenic activity associated with racemic ketorolac (52,53). 
The COX enzyme family consists of two enzymes, COX-1 and COX-2. COX-1 is 
found throughout the body and is responsible for synthesizing prostaglandins 
from arachidonic acid (53). Prostaglandins have an active role in 
vasoconstriction, vasodilation and immunosuppression, a protective role in 
maintaining the stomach and gastrointestinal lining, and ensure proper renal 
function in compromised kidneys (53–58). Prostaglandins also promote 
malignant tumor development and growth (53,54,58–60). COX-2 is found mainly 
in areas of inflammation, as well as the brain and spinal cord (54).  COX-2 
contributes to the synthesis of prostaglandins in inflamed tissues and malignant 
tumors and has been found to promote growth factor and matrix 
metalloproteinase (MMP) expression (53,61). MMPs enable tumor cells to invade 
basement membranes, penetrate blood vessels and metastasize (62).  
Inflammation accompanying breast cancer surgery is believed to 
exacerbate the escape of tumor stem cells and contribute to recurrent disease 
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(47,63). (S)-ketorolac may decrease tumor metastasis by acting as a COX 
inhibitor, thus decreasing inflammation. Cancer patients are known to have 
circulating tumor cells (CTCs) (64,65). In an inflammatory environment, the 
vasculature becomes “leaky” enabling CTCs to extravasate and move into distant 
tissues (47,63). Administering an NSAID such as ketorolac, perioperatively, may 
decrease tumor metastasis by acting as a COX inhibitor, thus decreasing the 
inflammatory response and preventing the escape of CTCs from the vasculature. 
In addition, ketorolac may prevent angiogenesis, which is another contributing 
factor to metastatic growth of CTCs (47,63). However, evidence shows that (R)-
ketorolac may also be playing an important role in preventing metastasis 
(45,50,51). 
 (R)-ketorolac interferes with the activation of Rho GTPase signaling proteins 
Rac1 and Cdc42 (40,45,50). Small Rho GTPases such as RhoA, RhoC, Rac1, 
and Cdc42, regulate cell growth, invasion, motility, and metastasis and are often 
found overexpressed in many cancers including breast cancer (66–70). Rho 
GTPases are particularly found in highly metastatic breast tumors and 
overexpression is associated with greater cancer severity (67,68,70). Aberrant 
Rho-GTPase signaling rather than mutation is responsible for cancer cell growth 
and progression.  
The (R)- enantiomer of ketorolac exhibits analgesic properties with little to 
none of the ulcerogenic properties seen with (S)-ketorolac (48,49). Unlike (S)-
ketorolac, (R)-ketorolac does not have an effect on COX activity, which 
consequently allows the enzyme to maintain its protective role in the stomach 
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and gastrointestinal linings (48,52). In one study investigating the ability of 
compounds to inhibit COX, (S)-ketorolac outperformed (R,S)-ketorolac, followed 
by a number of other COX inhibitors and (R)-ketorolac at the very end of the list, 
with the least amount of COX inhibition observed (71). However, (R)-ketorolac is 
not pharmacologically inactive, as previously thought. In epithelial cancer cells, 
(R)-ketorolac is able to inhibit Rac1 and Cdc42 activity in a comparable manner 
to established Rac1 and Cdc42 inhibitors (45,50,51). Docking studies have 
suggested that (R)-ketorolac’s configuration enables the carboxylate moieties of 
the molecule to chelate magnesium and disables the DOCK GEF’s ability to bind 
to Rac1 and Cdc42 (51). (R)-ketorolac has been shown to selectively bind Rac1 
and Cdc42 (51). These Rho-GTPases are necessary for the formation of 
lamellipodia and filapodia formation which enable a cell to migrate through its 
environment, invade basement membranes, and metastasize to distant locations 
(72,73).  
1.6 GTPases in Breast Cancer 
 (R)-ketorolac interferes with the activation of signaling proteins Rac1 and 
Cdc42 within the Rho GTPase family (40,45,50). Rho GTPases are enzymes that 
act as regulatory switches by binding to guanosine triphosphate (GTP), 
hydrolyzing it to guanosine diphosphate (GDP), effectively switching a signaling 
mechanism from an active “on” form to an inactive “off” form and back again 
(74,75).  
 GTPases play an important role in breast cancer. Small Rho GTPases 
have roles in cell growth, invasion, motility, and metastasis of breast cancer cells 
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(reviewed (66)). Most often, overexpression rather than mutations of Rho 
GTPases are found in cancerous tissue (reviewed (66)). Only one Rho GTPase 
genetic mutation, a mutation in RhoH, has been implicated in human cancer 
(76,77). RhoA, RhoC, Rac1, and Cdc42, are overly abundant in multiple cancers, 
including breast cancer (67–70). Rac1b, a splice variant of Rac1, is 
overexpressed in colon and breast cancer and is found primarily in the GTP-
bound active form because it is self-activating and thus GEF independent 
(69,78). Overexpression of a constitutively active GTPase can lead to 
uncontrolled cell growth and metastasis. Although Rac1b expression is increased 
in colorectal tumors when compared to normal colonic mucosa, and studies have 
found greater levels of Rac1 in malignant breast tissue, when compared to 
benign breast tissue, Rac1b expression levels are not different between 
malignant and benign breast tumor tissue (69,78,79). Another mutant, Rac1 
(P29S) is a fast cycling mutant, meaning that it is more often found in a GTP 
bound, or active state, due to increased GDP disassociation (80). The Rac1 
(P29S) mutation is found in breast cancer as well as head and neck cancers, and 
melanoma (80,81). Integral to the signaling cascade that activates cell growth 
and motility, Rho GTPases are often overexpressed in highly metastatic breast 
tumors and have been found to correlate positively with breast cancer severity 
(67,68,70).   
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1.7 Rho GTPases and Their Regulation 
 Changes in GTPase regulators, GEFs, GAPs and GDIs, cause Rho GTPases 
to be aberrantly regulated through mutation or GTPases splicing (Rac1b), 
altering the ability of cells to properly regulate the cytoskeleton leading to 
uncontrolled cell growth and migration. Rho GTPases are regulated by three 
different classes of proteins called guanine nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs) and guanine nucleotide dissociation 
inhibitors (GDIs) (82). GEFs, GAPs and GDIs function as Rho-GTPase 
regulators, cycling GTPase through active and inactive forms. GEFs facilitate the 
exchange of GDP for GTP; GAPs coordinate the dephosphorylation of 
nucleotides, converting GTP to GDP, and GDIs inhibit GEFs and GAPs from 
acting on Rho-proteins preventing the exchange of GTP and GDP (75). 
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Figure 1.1 The Rho-GTPase Regulation 
(adapted from (74,82)) 
 In their inactive form, GTPases are mainly located in the cytoplasm with their 
C-terminal tail bound by GDIs, which is necessary for plasma membrane 
localization (74,82). Dissociation from GDIs allows GTPases to relocate to the 
plasma membrane (74,82). External stimuli to membrane receptors induces the 
activation of membrane bound GTPases by GEFs which then causes GTPases 
to bind to effector proteins (74,82). This binding of effector proteins leads to 
downstream signaling which can be subsequently turned off by the 
dephosphorylation and inactivation of GTPases by GAPs (74,82).     
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For example, the cell surface tyrosine-kinase receptor, HER2, interacts 
with ligands and dimerizes (11). This signaling also increases GTPase cycling 
and increases the active status of GTPases. HER2 dimerization recruits a GEF, 
to the cell surface which exchanges GDP for GTP, activating Rac1 (11,83). Rac1 
binds to an effector protein, such as p21-activated serine/threonine kinase 1 
(PAK1). PAK family members phosphorylate multiple downstream proteins 
involved in breast cancer progression (reviewed (84)). One target of PAK1 is 
mitogen-activated protein kinase (MAPK) which itself is involved in multiple pro-
cancer functions such as proliferation, differentiation, motility, apoptosis, and 
survival (reviewed (84)).  
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Figure 1.2 Downstream Effectors and Cancer Implications 
An activated receptor (HER2, ER) activates GEFs (Tiam1, p190RhoGEF), 
phosphorylating and activating Rho-GTPases (Rac1, Cdc42, RhoA). Rho-
GTPases activate effector proteins (PAK, ROCK) that then activate multiple 
cellular proteins (MAPK, VEGF) involved in cancer (growth, motility, 
angiogenesis, survival, differentiation).  
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 Rho GTPases play important roles in actin and cytoskeleton regulation. In a 
cancer cell, regulation of cytoskeletal structure, adhesion, spreading, and polarity 
are vital to enabling the cell to migrate and metastasize (74,75,82,85). There are 
six distinct groups of Rho GTPases: the Rho, Rac, Cdc42-like, Rnd, RhoBTB, 
and Miro proteins (82). Of these, the best characterized, and the focus of our 
studies, are Cdc42, RhoA, and Rac1. 
 Cdc42 is responsible for cell polarity and regulates actin filament assembly, 
forming filopodia at the cell periphery (86–88). While Cdc42 is not directly 
responsible for cell growth or protrusion, it helps to direct cellular asymmetry 
(74). This asymmetry creates a leading edge for the rest of the cell to follow 
during activities such as migration (74). Directed activity towards the leading 
edge of the cell enables the cell to move in one unified direction. Increased 
protein levels of Cdc42 have been observed in breast cancer (67,68). However, 
an increase in Cdc42 proteins does not correlate with an increase in metastatic 
potential (89).  
 RhoA plays a role in contractile actin-myosin bundle (stress fiber) formation 
(88,90). RhoA’s contractile activity on the actin-myosin filaments enable the 
trailing edge of the cell to be pulled along as the front of the cell protrudes 
forward during cell movement (91). RhoA is also involved in signaling pathways 
such as Rho-associated coiled-coil-containing protein kinase (ROCK) activation 
pathway and the PI3-K/AKT pathway, which are essential for the actin 
polymerization during cell locomotion, and cell survival and expression of cell 
proliferation genes respectively (92). Increased amounts of RhoA protein are 
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found in advanced breast tumors while little RhoA is detected in surrounding 
tissues (67,68). Experiments injecting anti-RhoA silencing RNA (siRNA) into 
xenografted MDA-MB-231 breast tumors directly target RhoA containing tumor 
cells, and have shown great promise in inhibiting growth and angiogenesis (93).  
 Rac1 regulates actin polymerization at the cell periphery which creates 
lamellipodia and cell membrane ruffling (72,88). Rac activity at the leading edge 
of the cell allows it to form membrane protrusions which drive cell movement 
during invasion and migration (74). In breast cancer, there is a direct correlation 
between increased Rac1 protein and metastatic potential (89). Furthermore, 
Rac1 is overexpressed in malignant breast tissue when compared to benign 
breast tissue, and patients with more aggressive and recurring breast cancer 
have increased membrane localization of Rac1 (67–69).  
 One Rho GTPase regulator implicated in breast cancer is deleted in liver 
cancer 1 (DLC-1). The deregulation of DLC-1 is involved in the formation and 
progression of breast tumors (94). DLC-1 is a Rho GAP specific for RhoA and 
Cdc42, and has an important role in actin filament formation and focal adhesions 
(95). The DLC-1 gene acts as a tumor suppressor gene in breast cancer and 
genomic deletion of DLC-1 is associated with a variety of cancers including lung, 
breast, prostate, kidney, colon, uterus, ovary, liver and stomach (reviewed 
(94,96)). In addition to suppressing tumor growth, DLC-1 has been shown to be a 
metastasis suppressor in breast cancer cells (97). When DLC-1 is artificially 
overexpressed in vitro, a decrease in cell growth and colony formation can be 
observed, while the introduction of DLC-1 cDNA in vivo abolishes the 
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tumorigenecity of cancer cells in nude mice, supporting its role as a tumor 
suppressor (94,98).  
 Another Rho GTPase regulator is T-cell lymphoma invasion and metastasis-
inducing protein 1 (Tiam1) (99). Tiam1 is a fast-cycling GEF exchange factor for 
Rac, which is responsible for lamellipodia formation necessary for cell movement 
during migration and invasion (74,100). Tiam1 controls the functioning of cell-cell 
adhesions including tight junctions and E-cadherin based adherens junctions 
(101,102). Any disruption in these cell-cell adhesions allows tumor cells the 
opportunity to invade the circulatory system and metastasize. Like most 
biological systems, maintaining proper function regarding Tiam1 is a fine 
balancing act. Loss of Tiam1 causes cells to undergo epithelial mesenchymal 
transition (EMT), which results in the loss polarity and cell-cell adhesion 
properties leading to invasive tendencies (101,102). However, increased Tiam1 
also correlates to an increase in the invasiveness and advanced degree of 
progression particularly in breast cancer (103,104).  
  While Rho-GTPases play important roles in tumorigenesis, it is imperative to 
consider upstream signaling proteins. For example, one experiment investigating 
Tiam1 function in mammary tumorigenesis crossed Tiam1 knockout (Tiam1-/-) 
mice with breast cancer prone HER2/neu or Myc mice (105). Mammary tumor 
formation was not affected in the Tiam1-/-;Myc mice, but it was impaired in the 
Tiam1-/-;neu crosses, suggesting a vital role for Tiam1/Rac interaction in 
HER2/neu tumors (105). 
 
20 
 
1.8 The PyMT Mouse Model of Breast Cancer 
 Simulating the intricacies of a living system in vitro is complicated, 
expensive and unfeasible. Manipulated animal models are important tools in 
scientific research and aid in understanding how cellular pathways, drug 
treatments, etc. might function in a complex system. 
The mouse mammary tumor virus-polyoma middle T-antigen (MMTV-
PyMT) mouse model is a genetically engineered metastatic breast cancer model, 
functioning similar to human metastatic breast cancer both histologically and 
molecularly (106). Cancer in this mouse model is characterized by “short latency, 
high penetrance, and a high incidence of lung metastasis occurring 
independently of pregnancy and with a reproducible kinetics of progression” 
(107). Like human breast cancer, these mice gradually lose steroid hormone 
receptors such as the estrogen and progesterone receptors, and they 
overexpress HER2 and cyclin D1 which is associated with higher rates of breast 
cancer (13,108–110). Additionally, advanced cases of mammary gland tumors 
develop metastatic lesions in the lung and lymph nodes.  
“In the MMTV-PyMT mouse model, the mouse mammary tumor virus 
(MMTV) promoter drives the expression of Polyoma Middle T-Antigen (PyMT) in 
the mammary epithelium and other organs” (111). PyMT, a scaffold protein, 
binds and activates members of the tyrosine kinase family activating cellular 
signaling pathways including the Ras/Raf/MEK and PI3K/Akt pathways which 
play vital roles in cell growth (112,113). Activation of these signaling proteins 
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leads to mammary epithelium transformation and the appearance of multifocal 
mammary adenocarcinomas (111).  
In mouse mammary glands, terminal end buds form when the mouse goes 
through puberty and ovarian hormones are released (107). These terminal end 
buds invade the mammary gland fat pads forming branches (107). During 
pregnancy and lactation epithelial differentiation occurs and afterwards apoptosis 
and redifferentiation allow the epithelial cells to return to normal (107). The 
processes that allow the mammary gland to change for lactation and back again 
are the same processes that are exploited by cancerous cells to grow and invade 
tissue (107). Expression of PyMT causes transformation of the mammary 
epithelium independent of pregnancy related hormones. These changes result in 
the growth of adenocarcinomas in the mammary glands followed by metastasis 
to the lung and lymph nodes (106,111). The changes that occur in MMTV-PyMT 
mice during mammary gland tumor formation, including hyperplasia, adenoma, 
and early/late carcinoma are the same processes that occur in humans which 
makes this mouse ideal models for human breast cancer (114). 
1.9 Objective Study 
 The purpose of this study was to characterize a role for (R)-ketorolac as a 
breast cancer growth and metastasis inhibitor. Breast cancer is a deadly disease 
that can be difficult to treat due to its heterogenic nature and ability to develop 
resistance to available treatments. Racemic ketorolac has shown promise of 
being effective at preventing early relapse in breast cancer patients, but is 
contraindicated for long term use (43).  
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Using high throughput screening and cheminformatics approaches, the 
(R)- enantiomer of ketorolac was identified as a selective inhibitor for Rac1 and 
Cdc42 activation (51). Docking predictions of (R)-ketorolac on Rac1 and Cdc42 
suggest that the rotational configuration of (R)-ketorolac exposes carboxylate 
moieties which allows for the chelation of magnesium, leading potentially to 
nucleotide dissociation (disintegration of Rho-GTPase binding) (51).  
Recent work has shown that (R)-ketorolac directly inhibits Rac1 and 
Cdc42, but not RhoA, through an allosteric mechanism preventing invasion and 
metastasis in ovarian cancer (45,50). We hypothesize that (R)-ketorolac 
selectively inhibits Rac1 and Cdc42 activity in breast cancer, leading to a 
significant decrease in mammary tumor invasion and metastasis. Our focus on 
(R)-ketorolac will lead to the repurposing of an FDA approved drug as a new 
non-cytotoxic therapeutic for breast cancer.  
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Figure 1.3 Hypothesized Mechanism of Action of (R)-Ketorolac 
We hypothesize that (R)-ketorolac selectively binds to Rho-GTPases, Rac1 and 
Cdc42, preventing the binding of GTP and thus activation of downstream effector 
proteins involved in cell signaling pathways important in breast cancer cell 
invasion and migration.   
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2. THE EFFECTS OF KETOROLAC AND ITS ENANTIOMERS ON 
BREAST CANCER CELLS IN VITRO 
2.1 Introduction 
 Small molecule screening of the Prestwick Chemical Library® coupled 
with cheminformatics analysis has identified the (R)- enantiomer of ketorolac as 
having a binding affinity for members of the Rho-GTPase family (40). Racemic 
ketorolac is an NSAID routinely given to patients in a clinical setting to manage 
pain and inflammation (48). Patients receiving racemic ketorolac when 
undergoing tumor reduction surgery demonstrate an improved outcome in both 
ovarian and breast cancer cases (45,47,115). Until recently, assumptions were 
made that only the (S)- enantiomer of ketorolac had activity, while the (R)- 
enantiomer was inert (48,71).  However, recently (R)-ketorolac has been shown 
to be a selective inhibitor of Rac1 and Cdc42, affecting downstream signaling 
pathways involved in cellular invasion and migration in ovarian cancer cells (50). 
 GTPases are predicted to regulate proliferation and invasion. In a cell, 
growth and movement rely on the coordination of polymerization and 
depolymerization of actin and microtubule dimers that make up the cytoskeleton. 
This coordination is regulated by cell signaling pathways requiring the activation 
and deactivation of multiple signaling proteins, including Rho-GTPases. As 
discussed previously, Rho-GTPases Cdc42, RhoA, and Rac1 work together to 
direct actin polymerization near the leading edge of a cell for protrusion and 
forward movement, and depolymerize actin near the trailing edge of the cell for 
membrane retraction (74,72,88,91). These same actions, regulated by the same 
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Rho-GTPases are also important when directing the cytoskeleton in cell division 
during growth (75). Previous research has demonstrated the vital role played by 
Rho-GTPases in cell proliferation and invasion. When any one of these 
regulatory proteins is knocked out or disabled, there is a significant decrease in 
the ability of cells to proliferate and invade (reviewed (75)). Using (R)-ketorolac to 
bind to and inhibit Rho-GTPase proteins is predicted to interfere with 
coordination of the cytoskeleton, interfering with tumor cell proliferation and 
invasion, but not cell viability. 
(R)-ketorolac’s ability to inhibit Rho-GTPases in ovarian cancer cells, and 
the positive effects racemic ketorolac has on preventing relapse in ovarian and 
breast cancer patients, has prompted us to study the mechanism of action of (R)-
ketorolac in breast cancer cells. In this study we were interested in distinguishing 
the differences between (R)- and (S)- ketorolac on proliferation and invasion. 
Viability assays were conducted on breast cancer cell monolayers and MCAs 
using both an invasive breast cancer cell line, MDA-MB-231, and a non-invasive 
breast cancer cell line, MCF-7. Ketorolac’s interaction with normal cell cycle was 
assessed using flow cytometry. Colony forming assays were conducted to 
examine the effects of ketorolac on cell growth. Migration assays were performed 
to determine if ketorolac inhibited the migratory ability of breast cancer cells. 
Finally, MMP9, an enzyme involved in the breakdown of the extracellular matrix, 
was measured in ketorolac treated cells. 
 
26 
 
2.2 Materials and Methods 
2.2.1 Materials 
 Ketorolac-tris salt was purchased from Sigma-Aldrich and made into 10 
mM stock aliquots in deionized (DI) water. (R)- and (S)- ketorolac enantiomers 
were purchased from Toronto Research Chemicals and reconstituted according 
to the package instructions. Etoposide was purchased from Trevigen. Taxol was 
purchased from Enzo Lifesciences. 
2.2.2 Cell Culture  
MCF-7 cells (non-invasive human breast adenocarcinoma) and MDA-MB-
231 (invasive human breast adenocarcinoma) cells were a generous gift from Dr. 
Kristina Trujillo (Department of Cell Biology and Physiology, UNM, Albuquerque, 
NM). MCF-7 and MDA-MB-231 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS 
(Atlanta Biologicals, Norcross, GA), 1% penicillin/streptomycin (Gibco, Grand 
Island, NY) and 1% Insulin-Transferrin Selenium-A (Gibco, Grand Island, NY). 
Cells were split 1:3 when they had reached 70-80% confluency. OVCA 433 cells 
(epithelial ovarian cancer cells) were provided by Dr. Robert Bast Jr., M.D. 
Anderson Cancer Center, Houston TX and grown in DMEM supplemented with 
10% FBS, 0.5% penicillin/streptomycin, and 1% L-glutamine (Gibco, Grand 
Island, NY), and 1% sodium pyruvate (Sigma-Aldrich, St. Louis, MO). Cells were 
split 1:4 when they had reached 70-80% confluency. All cell lines were incubated 
at 37⁰C and 5% CO2. 
 
27 
 
2.2.3 MCF-7 Monolayer and MCA Viability with Racemic Ketorolac  
MCF-7 cells were seeded at 15,000 cells/mL (100 µL/well) into flat bottom 
96-well plates, for monolayers, and into Lipidore U-bottom 96-well plates, for 
multi-cellular aggregates (MCAs), and incubated overnight at 37⁰C and 5% CO2. 
A 10 mM ketorolac stock in DI water was diluted with cell culture medium to a 
300 µM ketorolac stock. Eight stock treatments were further created by diluting 
the 300 µM ketorolac stock solution with cell culture medium. 50 µL of each stock 
treatment was added to respective wells, which already contained 100 µL of 
media for the final indicated concentrations. 
An 80 µM etoposide stock solution in cell culture media was used as a 
positive control, adding 50 µL into each well containing cells and 100 µL of cell 
culture media for final well concentrations of 40 µM etoposide. Cells were treated 
in quadruplicate, in both MCA and monolayer plates. The plates were tapped 
gently to mix and incubated for 48 hours. After the incubation period, 15 µL of 
10X PrestoBlue (Invitrogen, Carlsbad, CA) was added to each well, the plate was 
tapped gently to mix and incubated at 37⁰C. Well fluorescence readings were 
taken on a SpectraMax M2 plate reader at 2, 4, 6, and 24 hours. The experiment 
was repeated a total of three times using the 24 hour PrestoBlue time point. 
2.2.4 MCF-7 and MDA-MB-231 Monolayer Viability with Ketorolac 
Enantiomers  
MCF-7 and MDA-MB-231 cells were plated into 96-well plates at 15,000 
cells/mL (100 µL/well) and allowed to adhere overnight in 37⁰C and 5% CO2 
conditions. 300 µM stock solutions of each racemic ketorolac, (R)-ketorolac, and 
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(S)-ketorolac were made in supplemented DMEM media, and 240 µM stock 
solution of etoposide was made in supplemented DMEM media as a control. In 
quadruplicate, 50 µL of drug-free supplemented DMEM media was added to all 
wells designated as non-treated wells and empty wells, with no cells. 50 µL of 
each of the corresponding stock solutions were added to their respective wells 
for final well concentrations of 100 µM of each ketorolac treatment and 80 µM of 
etoposide treatment. The plate was tapped gently to mix and incubated for two 
days. After the incubation period, 15 µL of 10X PrestoBlue was added to each 
well and the plate was returned to the incubator. Well absorbency readings were 
taken at 2, 4, 6, and 24 hours. A one-way ANOVA statistical analysis with a 
Dunnett’s multiple comparison test was used to compare all treatment groups. 
This experiment was repeated three times. 
2.2.5 MCF-7 Cell Cycle with Racemic Ketorolac  
MCF-7 cells were seeded at 2.5 x 105 cells/mL with 1 mL/well into 24-well 
plates and allowed to adhere overnight. Ketorolac stock solutions were made in 
supplemented DMEM media at 10 µM, 30 µM, 100 µM, and 300 µM from a 10 
mM ketorolac stock and 0.5 µM taxol was used as a positive control.  
Old DMEM was removed and new DMEM containing ketorolac was added 
to the wells in triplicate at 1 mL/well. Cells were incubated for 48 hours then 
washed once with 1X PBS. A few drops of trypsin were used in each well to 
detach adherent cells then neutralized with DMEM. Samples were moved into 15 
mL conical tubes, pelleted, and supernatant was removed. Each sample was re-
suspended in 5 mL of PBS and centrifuged at 2500 rpm for 5 minutes as a 
29 
 
washing step. Supernatant was again removed, samples were re-suspended in 1 
mL of freshly made propidium iodide (PI) staining solution and incubated for 30 
minutes. PI dye was made by mixing 20 mL of 0.1% Triton X-100 in 1X PBS, 40 
µL DNAse-free RNAse-A (100 mg/mL in PBS) (2 mg total) and 800 µL of 500 
µg/mL PI stock. Samples were analyzed on a Becton Dickinson FACScan flow 
cytometer (Immunocytometry Systems) at 20,000 events. Three independent 
experiments were conducted and a two-way ANOVA with a Bonferroni post-test 
was used to calculate significance.  
2.2.6 Colony Forming Assays – MDA-MB-231 
 MDA-MB-231 cells (500 cells/mL) were plated in a 24-well plate at 1 
mL/well and incubated in 37⁰C and 5% CO2 conditions to adhere overnight. Cells 
were treated in triplicate with either 100 µM racemic ketorolac or the same 
volume of cell culture media as a control. The cells were allowed to grow for 16 
days after treatment. Cells were replenished with fresh culture media and drug 
on day 6.  Intermittently throughout the study, three areas of each well were 
imaged with the 4X objective and the number of colonies observed in the three 
images for each well was recorded. Image J software was used to calculate the 
total area of colony growth for each well. Total area and total colony number per 
well were calculated and results from the three wells per treatment were 
averaged. Results were normalized to the placebo control. 
2.2.7 Invasion Assays – MDA-MB-231 
 Invasion assays were conducted using a Cultrex® 3-D Spheroid Cell 
Invasion Assay kit (Trevigenn Gaithersburg, MD) and MDA-MB-231 cells. Cells 
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were plated and treated according to the manufacturer’s protocol. These cells did 
not receive any treatment, as this was a test to see if the cells had invasive 
properties. MCAs were imaged over the course of 7 days.  
2.2.8 Migration Assays – MCF-7 and MDA-MB-231 
MCF-7 cells (5 x 104 cells/mL) and MCF10A cells (5 x 104 cells/mL) were 
grown in 8 micron pore Boyden chamber inserts (Becton Dickinson Labware). 
Cells were serum deprived for 24 hours before treating with 10 µM, 30 µM, 100 
µM, 300 µM ketorolac or 50 µM NSC23766 (Tocris Bioscience) as a control, 20 
nM EGF was added to half of the wells. Cells were allowed to migrate for 48 
hours and non-migratory cells were removed. Migratory cells were fixed in ice-
cold 100% methanol and stained with 0.02% crystal violet in 10% ethanol. 
Migratory cells were imaged and counted on an Olympus 1X70 inverted 
microscope. The total number of migratory cells present in three separate images 
per membrane were manually counted and averaged. Each migration assay was 
repeated a minimum of three times and significance was determined using a 1-
way ANOVA test. This work was performed in the Hudson lab by S. Ray Kenney. 
2.2.9 Zymography – MMP Expression 
Sample Preparation  
MCF-7, MDA-MB-231, and OVCA 433 cells were seeded into 6-well plates 
at 5 x 105 cells/mL at 1 mL/well and allowed to grow to 80% confluence in 37⁰C 
and 5% CO2 conditions. Cells were serum deprived by washing in PBS and 
replacing media with a low serum media containing 1% Bovine Serum Albumin 
(BSA) for at least 24 hours before adding ketorolac treatments. Cells were 
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pretreated with 0 µM, 10 µM or 100 µM ketorolac. The plates were incubated for 
two hours and then half of the wells received 10 nM EGF treatments. The plate 
was incubated for 24 hours then conditioned media and cell lysates were 
collected on ice. Media from each sample was transferred to epitubes and 
centrifuged at 1,000 g for 10 minutes to pellet cell debris. Aliquots of the 
centrifuged media were transferred into new epitubes and kept at -80⁰C until 
needed for further analysis. Sample wells were washed twice with cold PBS and 
then 70 µL of 0.1% Triton-X100 in PBS was added to each well and the plate 
was rocked at 4⁰C for 30 minutes to lyse cells. Lysate was scraped from the 
wells and moved to epitubes for 10 seconds of probe sonication using a Branson 
Sonifier Cell Disruptor 200, then centrifuged for 10 minutes at 10,000 g at 4⁰C. 
Supernatant was collected and stored at -80⁰C until needed for BSA protein 
assays. BSA protein assays were conducted to determine lysate protein 
concentration and thus relative media protein concentration as described in the 
Pierce Protein Assay Kit protocol.  
Gel Preparation and Electrophoresis  
Samples were run on a 10% SDS-polyacrylamide (Biorad) gel containing 
1.5% (w/v) gelatin (Sigma G-2625 gelatin 175 bloom). Conditioned medium (10 
µL), collected earlier from treated cells was combined with 4X non-reducing 
sample buffer (4.6 mL dH2O, 0.5 mL 1 M Tris pH 7.4, 1.5 mL glycerol, 0.8 mL 
20% SDS, 25 mg bromophenol blue) in a 1:3 sample to sample buffer ratio. Each 
sample was loaded on the gel along with a stained molecular weight (MW) 
marker. Gels were run on a Western blot apparatus at 95V until the bands 
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migrated through the stacking gel, then at 125V until the bands were near the 
bottom of the gel. Once the run was finished, gels were incubated for 30 minutes 
at room temperature in renaturing buffer (2.5% Triton X-100 (v/v) in dH2O), 
changed to developing buffer (50 mM Tris, pH 7.6, 0.2 M NaCl, 5 mM CaCl2, 
0.2% (w/v) Brij-35, dH2O pH 7.6) for 30 minutes and then left in fresh developing 
buffer for 24 hours at 37⁰C. Gels were then stained in 0.1% PhastGel Blue R 
(Sigma) in acetic acid for 30 minutes and destained in 10% acetic acid in dH2O 
overnight. Proteinase activity was indicated by the presence of zones of staining 
inhibition. Gels were imaged on a FluorChem R (ProteinSimple, San Jose, CA) 
and densitometry was analyzed using ProteinSimple AlphaView 3.4 software. 
Each experiment was repeated a minimum of three times. 
2.3 Results 
2.3.1 MCF-7 Monolayer and MCA Viability with Racemic Ketorolac  
Cell viability assays were performed on MCF-7 breast cancer cell lines to 
determine if racemic ketorolac affected viability. In both MCF-7 monolayers and 
the more organotypic multicellular aggregates (MCAs), ketorolac had no effect on 
cell viability after 48 hours of treatment. Etoposide, a DNA-topoisomerase II 
inhibitor known for inhibiting cell division by causing DNA strand breaks, was 
used as a positive control (116,117). Varying incubation times with PrestoBlue 
revealed the optimal time point at which to take plate readings. Incubation with 
PrestoBlue for 24 hours was used on all subsequent assays. A one-way ANOVA 
statistical analysis was used to compare all treatment groups. The etoposide 
treatment was the only group found to be significantly different from the control 
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with a p value < 0.05. Visual inspection of the cells showed little to no changes in 
morphology in cell density or MCA structure when comparing the non-treated and 
100 µM ketorolac-treated cells.  
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Figure 2.1 MCF-7 Viability with Racemic Ketorolac on MCAs and 
Monolayers at Multiple Time Points  
Viability assays were conducted on MCF-7 monolayers (A) and MCAs (B). 
Cells were treated for 48 hours and incubated with PrestoBlue at multiple 
time points to determine the optimal PrestoBlue incubation time. Etoposide 
was used as a positive control and was significantly different from the 
ketorolac treated cells (p < 0.05). There was no a change in cell viability with 
ketorolac treatment concentrations up to 100 µM. Twenty-four hours was 
chosen as the optimal PrestoBlue incubation time due to the small variability 
in relative fluorescence when compared to other time points.  
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Figure 2.2 MCF-7 Viability on MCAs and Monolayers with Racemic 
Ketorolac - Ketorolac has no effect on the viability of MCF-7 monolayer or 
MCA cells.  
MCF-7 monolayers (A) and MCAs (B) were treated with ketorolac for 48 hours. 
Representative images show no difference in cell morphology. Etoposide (80 µM) 
was added to MCF-7 monolayers and MCAs for 48 hours as a positive control. 
Cell viability was assessed using PrestoBlue and a colorimetric plate reader as 
described in the methods. A one-way ANOVA was used to calculate significance.   
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2.3.2 MCF-7 and MDA-MB-231 Monolayer Viability with Ketorolac 
Enantiomers at Varying PrestoBlue Incubation Times  
MCF-7 and MDA-MB-231 monolayer cells were treated with either 100 µM 
racemic ketorolac, (S)-ketorolac, (R)-ketorolac, or 80 µM etoposide. In MCF-7 
monolayers, at the 2, 4, and 6 hour PrestoBlue time points, (S)-ketorolac had a 
statistically significant increase in fluorescence from the untreated control with a 
p < 0.05. At 24 hours incubation with PrestoBlue, (S)-ketorolac treatment was no 
longer statistically different from the untreated control. Racemic and (R)-ketorolac 
treatments in MCF-7 monolayers were not different from the untreated control at 
any of the PrestoBlue incubation time points.  
None of the ketorolac treatment groups were statistically different from the 
control group in MDA-MB-231 monolayers at any of the incubation time points. In 
both experiments, etoposide was statistically decreased from the untreated 
control at all PrestoBlue time points, with p-value of p<0.05. A one-way ANOVA 
statistical analysis with a Dunnett’s multiple comparison test was used to 
compare all treatment groups. It is worth noting that the etoposide treatment 
group’s relative fluorescence (an indication of cell viability) was about half that of 
the normalized control group in the MCF-7 cells but much closer to about 75% of 
the control group in the MDA-MB-231 cells. As MDA-MB-231s are a more 
aggressive cell line than MCF-7s, this may indicate a greater resistance to 
topoisomerase II inhibitors.  
  
37 
 
 
Figure 2.3 MCF-7 Monolayer Viability with Ketorolac Enantiomers  
Racemic ketorolac and its enantiomers are non-cytotoxic to MCF-7 monolayers 
at 100 µM concentrations. Cell viability with (S)-ketorolac treatment was 
significantly greater than other treatments at 2, 4, and 6 hours incubation with 
PrestoBlue but at 24 hours fell within the same range as the other treatments. 
Etoposide significantly decreased cell viability at all time points.   
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Figure 2.4 MDA-MB-231 Monolayer Viability with Ketorolac Enantiomers 
 Racemic ketorolac and its enantiomers are non-cytotoxic to MDA-MB-231 
monolayers at 100 µM concentrations. Etoposide significantly decreased cell 
viability at all time points. 
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2.3.3. Cell Cycle in MCF-7, and MDA-MB-231 Cells Treated with Ketorolac  
 Cell cycle analysis was performed using flow cytometry to determine if 
racemic ketorolac causes cell cycle arrest and if it was dose dependent. When 
cells were treated with 10, 30, 100 and 300 µM ketorolac, there was no change in 
the cell cycle phase populations when compared to the non-treated (NT) control 
group. About 20% of cells were in Go, 10% in S, and 70% in G2/M phase in MCF-
7 cell lines. In MDA-MB-231 cells, about 30% of cells were in Go, 60% in S, and 
10% in G2/M phase. Paclitaxel, a mitotic inhibitor, was used at 0.5 µM as a 
positive control and showed statistically significant changes in cell cycle when 
compared to control treatments. In MCF-7 cell lines, the paclitaxel treated cells 
had a greater percentage of cells in the Go phase, and fewer cells in the G2/M 
phase, while there was no difference between any of the treatment groups for the 
S phase of cell cycle.  In MDA-MB-231 cells paclitaxel treated cells had a greater 
percentage of cells in the Go phase, and less cells in the S phase, while there 
was no difference between any of the treatment groups for the G2/M phase of cell 
cycle. Significance was determined using a two-way ANOVA analysis with a 
Bonferroni post-test. Significant differences had p-values of p < 0.001. 
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Figure 2.5 Ketorolac Does Not Change Cell Cycle of MCF-7 Cells at 
Concentrations Up To 300 µM 
MCF-7 cells were treated with ketorolac and cell cycle was analyzed using flow 
cytometry. Ketorolac does not arrest the cell cycle in MCF-7 cells at 
concentrations up to 300 µM. Ketorolac treated cells have the same percent of 
cells in each phase of the cell cycle as the NT control. Taxol was used as a 
positive control and had a significant percent of cells arrested in the Go phase of 
the cell cycle when compared to the NT control.  
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Figure 2.6 Ketorolac and Its Enantiomers Do Not Affect Cell Cycle in MCF-7 
and MDA-MB-231 Cells at 100 µM Concentrations 
MCF-7 (A) and MDA-MB-231 (B) cells were treated with 100 µM of ketorolac or 
ketorolac enantiomers and cell cycle was analyzed using flow cytometry. In MCF-
7 and MDA-MB-231 cells, racemic ketorolac and its enantiomers did not cause 
cell cycle arrest. The Taxol control had a significant percent of cells arrested in 
the Go phase of the cell cycle when compared to the NT control. 
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2.3.4 Colony Forming Assays – MDA-MB-231 
 MDA-MB-231 cells were treated with 100 µM ketorolac and imaged for 
colony formation over 16 days. The total number of colonies formed reached a 
peak at day 6 in both placebo and ketorolac treated cells, with the placebo 
treated cells forming more individual colonies than the ketorolac treated cells. As 
the experiment progressed, individual colonies merged into larger, single 
colonies, resulting in fewer total numbers of colonies counted. By day 16, many 
of the cells had died and there was only cell debris floating in the media. The 
total area of colony formation increased over the course of the study and then 
decreased at day 16 due to cell death from age. Overall, the placebo cells had 
more growth than the ketorolac treated cells. Ketorolac treatment inhibited MDA-
MB-231 cell colony formation and growth. These assays were repeated a 
minimum of three times and analyzed using at two-way ANOVA. Although trends 
were observed, changes in colony formation over time were not significant 
between treatment groups. 
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Figure 2.7 Ketorolac Inhibits MDA-MB-231 Colony Formation 
MDA-MB-231 cells were plated sparsely, treated with 100 µM racemic ketorolac, 
and imaged for 16 days. The number of individual colonies formed, increased 
and then slowly decreased over time as multiple colonies merged onto a single 
larger colony. Placebo treated cells grew greater numbers of colonies than 
ketorolac treated cells (A). The total area of colonies increased over time but 
ketorolac treatment inhibited total area growth of colonies. (B). Representative 
images are shown (C). 
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2.3.5 Invasion Assays – MDA-MB-231 
 MDA-MB-231 cells were plated according to protocol instructions using 
the Cultrex® 3-D Spheroid Cell Invasion Assay kit (118). In the kit’s example, 
MDA-MB-231 MCAs that did not receive matrix remained a similar size to the 
starting MCA. MDA-MB-231 MCAs that received the invasion matrix grew in area 
over the course of the study (Fig 2.8 A & B) (118). When the MDA-MB-231 cells 
in our lab were analyzed followed using the kit protocol, MCAs resembled those 
in the kit example that had not received invasion matrix (Fig 2.8 C). The MCAs 
did not change significantly in area over the course of the study (Fig 2.8 D).  
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Figure 2.8 MDA-MB-231 Cells Did Not Exhibit Expected Invasive Properties 
The invasion assay showed images of MDA-MB-231 cells under invasive and 
non-invasive conditions. With matrix, cells invaded and without matrix they did 
not invade (A) (118). The protocol’s example graph of MCA diameter shows 
increased area over the course of the study (B) (118). The MDA-MB-231 cells in 
our lab were not invasive. The cells resembled the cells in the protocol that were 
not given matrix (C). The MCAs remained small and did not significantly increase 
in area over the course of the study (D). 
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2.3.5 Migration Assays – MCF-7 and MDA-MB-231 
 MCF-7 and MCF-10A cells were treated with ketorolac at increasing 
concentrations. There was a dose dependent decrease in the number of cells 
that were able to migrate through the Boyden chamber pores. The experiment 
was repeated a minimum of three times and results were found to be statistically 
significant using a 1-way ANOVA test. This work was conducted by S. Ray 
Kenney. 
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Figure 2.9 Ketorolac Inhibits MCF-7 and MCF-10A Migration in a Dose 
Dependent Manner  
Migration was inhibited by ketorolac treatment. Increasing concentrations of 
ketorolac resulted in fewer migratory cells in both MCF-7 (A) and MCF-10A (B) 
cell lines. Migrations assays were done by Dr. S. Ray Kenney. 
  
48 
 
2.3.6 MMP Expression 
 Matrix metalloproteinase 9 (MMP9) expression was measured in the 
media of MCF-7 and MDA-MB-231 cells treated with ketorolac and 
supplemented with epidermal growth factor (EGF).  While MMP9 activity was 
present in all the samples, there was no significant difference between treatment 
groups in either the MCF-7 cells or the MDA-MB-231 cells. Changes in MMP9 
activity in MCF-7 cells were not expected because it is a non-invasive cell line, 
but there was no change in the MDA-MB-231 invasive cell line either. These 
results suggest that ketorolac treatment is not affecting the baseline MMP9 
activity. Additionally, the MDA-MB-231 cells are not expressing the invasive 
qualities expected from this cell line. The experiment was repeated three times 
and results were analyzed using a student’s t-test. 
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Figure 2.10 MMP Expression Does Not Change with Ketorolac Treatment 
MCF-7 (A) and MDA-MB-231 (B) cells were treated with racemic ketorolac and 
EGF. Representative gel from MCF-7 cell samples show clear MMP9 bands (C). 
Protein and conditioned media was collected to examine the amount of MMP9 
enzyme present using zymograms. There was no significant change in the 
relative amount of MMP9 detected when treated samples were compared to non-
treated samples. MDA-MB-231 and MCF-7 cells had slightly more MMP9 present 
when treated with EGF in addition to the ketorolac and the amount of MMP9 
increased with increasing ketorolac concentration, but the change was not 
significant. Band density was normalized to the non-treated control. Statistics 
were conducted using a one way t-test. 
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2.4 Discussion 
These in vitro studies were conducted with two goals in mind. The first 
was to confirm that the ketorolac concentrations used in the studies were non-
toxic and the second was to test whether ketorolac decreases breast cancer cell 
proliferation. There is evidence that (R)-ketorolac inhibits Rho GTPase activity 
(51). Members of the Rho-GTPase family are important regulators of cellular 
functions involved in actin reorganization, cell migration, invasion, proliferation 
and growth (74). In epidemiological studies of breast cancer patients who were 
given ketorolac as part of their perioperative care, researchers identified a 
correlation between ketorolac administration and patient survival (43,115). Other 
studies have exhibited a positive correlation in the ability of (R)-ketorolac to 
inhibit ovarian cancer cell migration and invasion both in vitro and in clinical 
studies (45,50). These studies have led us to hypothesize that (R)-ketorolac acts 
in preventing breast cancer metastasis in much the same way as has been 
identified in ovarian cancer, by inhibiting the activity of Rho-GTPases, Rac1 and 
Cdc42. 
With the viability studies it was found that racemic ketorolac and its 
enantiomers do not affect the viability of MCF-7 or MDA-MB-231 cells in either 
monolayers or MCAs up to 300 µM concentrations. MCAs are more organotypic 
but, due to concerns that the drug and the viability assay reagent, PrestoBlue, 
did not penetrate the MCAs fully, monolayer viability assays were also 
conducted. Additionally, in some exploratory viability assays, after treating with 
ketorolac, MCAs were centrifuged in flat bottom plates to break apart and spread 
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out cells for full PrestoBlue penetration. This method did not make a difference in 
the cell viability results. Cell viability was the same in non-treated cells as in cells 
treated with ketorolac, suggesting that the drug is non-toxic. When cell viability is 
affected by a drug, there is less cell growth and fewer cells on the plate. At 
greater drug concentrations, cells that are present begin to form apoptotic blebs 
and have fewer protrusions. Finally, cells begin to pull off of the pate, forming 
spheroids and floating around the dish, and pieces of un-intact cellular 
membrane are present in the media. In our cell viability assays there were no 
visual changes in monolayer or MCA morphology, when cells were treated with 
ketorolac. Considering these findings, ketorolac does not decrease breast cancer 
metastasis by causing apoptosis, or cell death, in cancer cells.  
Colony forming assays were able to show that while ketorolac is non-toxic, 
it is able to inhibit cell growth and colony formation, without killing the cells. 
Breast cancer cells treated with ketorolac were able to grow and form colonies, 
but at a much slower rate than the placebo treated controls, leading us to 
hypothesize that the drug is impeding the cell’s ability to grow and divide.  
MCF-7 and MDA-MB-231 cells were treated with ketorolac and analyzed 
using flow cytometry to determine if ketorolac causes cell cycle arrest. One 
mechanism of some anti-cancer drugs, like paclitaxel, is interference with normal 
microtubule activity (reviewed (38)). When cells cannot properly regulate 
microtubule polymerization and depolymerization, the cell can get “stuck” in one 
phase of cell cycle, unable to complete mitosis. The roles Rac1 and Cdc42 have 
in cytoskeletal reorganization support the theory that arrest of these two Rho-
52 
 
GTPases may cause cell cycle arrest. When MCF-7 and MDA-MB-231 cells were 
treated with ketorolac, there was no cell cycle arrest observed. These results 
indicate that ketorolac does not affect the cytoskeletal polymerization or 
depolymerization abilities of breast cancer cells.  
Based on correlations between ketorolac administration and decreased 
breast cancer metastasis, we hypothesized that treating breast cancer cells in 
vitro with ketorolac would decrease their migration and invasion abilities (43,46).  
Zymograms using both MCF-7 and MDA-MB-231 cells were used to examine the 
effects ketorolac has on MMP9 expression. MMPs are enzymes used by the cell 
to break down basement membranes, penetrate through blood vessels and 
metastasize to distant locations (62). If ketorolac was affecting cell invasion and 
migration via MMP production, we should expect to see a decrease in MMP 
protein with increasing concentrations of ketorolac. MDA-MB-231 cells are known 
to be an invasive cell type, while MCF-7 cells are non-invasive, thus a more 
drastic change in MMP9 production in MDA-MB-231 cells than in MCF-7 cells 
was expected when treating with ketorolac. While zones of inhibition were 
observable and measurable in the zymogram gels, there was no significant 
difference in the band density between treatment groups suggesting that the 
ketorolac treatment is not affecting the invasiveness of the cells. Also, the MDA-
MB-231 cells in our lab do not have invasive qualities expected of them.  
Work done in our lab by S. Ray Kenney showed that when MCF-7 and 
MCF-10A cells were treated with ketorolac, they lost their ability to migrate in a 
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concentration dependent manner. These same migration assays were conducted 
in MDA-MB-231 cells and no change in migratory ability was observed.  
Invasion assays using untreated MDA-MB-231 cells were conducted to 
determine if our invasive breast cancer cell line was able to be invasive, however 
invasion into the matrix gel was not apparent. Combining these results with the 
lack of migration and considering there was no change in MMP9 expression 
when cells were treated with ketorolac, it was concluded that the MDA-MB-231 
cells in our laboratory are not the phenotypically normal MDA-MB-231 cells we 
expected to have. The MDA-MB-231 breast cancer cells in our laboratory do not 
exhibit the migratory and invasive characteristics expected of this cell line. These 
changes may have been caused by multiple factors such as undergoing too 
many passages or poor culturing techniques. New MDA-MB-231 cells should be 
obtained and the in vitro assays described here should be repeated.   
In future work it would be useful to conduct Western blots to examine the 
effects of (R)-ketorolac on downstream effectors of Rac1 and Cdc42 in breast 
cancer cells. This information may reveal the Rho-GTPase activation pathway 
that is affected by (R)-ketorolac and provide more insight to the exact mechanism 
of action of the drug.  
  
54 
 
3. THE EFFECTS OF KETOROLAC ON MAMMARY GLAND CANCER 
CELL PROLIFERATION AND A STUDY OF ITS POTENTIAL TOXICITY 
IN PYMT MICE 
3.1 Introduction 
 Breast cancer is the second most commonly diagnosed cancer in women 
after skin cancer (1). Its heterogeneity and multiple forms of induction, including 
genetic inheritance, and random mutation, make it a convoluted disease. 
Overexpression of cell surface receptors like HER2/neu can give rise to 
tumorigenesis by causing uncontrolled activation of proteins involved in cell 
growth and migration, angiogenesis and anti-apoptotic pathways. Testing anti-
cancer drugs in cell culture can tell us how various proteins and signaling 
pathways may be altered, but it cannot serve as a predictive measure for the 
complexities of a living system. Reliable animal models allow for the manipulation 
of signaling pathways involved in tumorigenesis and application of drug 
treatments before human testing. 
 MMTV-PyMT mice were chosen as the model system because of their 
similarities to human breast cancer as well as tumor formation characterized by a 
short latency and high lung metastasis incidence occurring independently of 
pregnancy (107). MMTV-PyMT mice develop primary mammary gland tumors 
around 4-8 weeks of age, externally visible tumors around 10 weeks of age, and 
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exhibit widespread lung metastasis around 12-14 weeks of age (108). 
 
Figure 3.1 MMTV-PyMT Mouse Mammary Tumor Development Timeline 
MMTV-PyMT mice develop palpable tumors around 8 weeks of age. Around 10 
weeks the tumors become large enough to observe externally and between 12 
and 14 weeks of age, the mammary tumors begin metastasizing to the lungs. 
 
As in humans, tumor formation in MMTV-PyMT mice can be categorized 
into multiple stages according to severity: hyperplasia, adenoma/mammary intra-
epithelial neoplasia, and early and late carcinoma (106). These similarities to 
human breast cancer allow us to examine the effects of anti-cancer drugs at 
various stages in cancer progression.  
In this study we were interested in the potential toxic effects and early 
therapeutic effects of ketorolac and its enantiomers on an organism. This study 
was also used to examine initial differences between enantiomer and racemic 
treatment groups and to provide information for future longer experiments. The 
mice in this study were examined for any signs of toxic side effects of the drugs 
and mammary gland samples were collected at the point when hyperplasia was 
just beginning to become apparent. We hypothesized that racemic ketorolac and 
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its enantiomers, at this stage, would not present any toxic effects to the organism 
and that we would observe few effects on early stage mammary gland tumors.  
 
Figure 3.2 In vivo Experimental Outline 
MMTV-PyMT mice were trained at 5 weeks old to consume a pill containing 
either ketorolac treatment or placebo treatment. In the short study mice 
consumed pills containing placebo, racemic ketorolac, (R)-ketorolac, or (S)-
ketorolac every 12 hours for 21 days. In the longer studies mice consumed pills 
containing placebo or (R)-ketorolac every 12 hours, 5 days a week for either 47 
(12 week old mice) or 64 (14 week old mice) days. At the end of the experiment, 
mice were sacrificed, their organs harvested and examined for signs of drug 
toxicity and tumor burden. (mouse image adapted from 
http://www.dianliwenmi.com/postimg_4436338_10.html) 
3.2 Materials and Methods 
3.2.1 Pill Preparation  
Estimating an average mouse weight of 22 g, mice were dosed with 1 
mg/kg ketorolac twice a day. Pills were made to contain 22 µg/pill ketorolac. To 
make 100 racemic ketorolac pills with, 2.2 mg ketorolac tris salt (Sigma #K1136) 
was dissolved in 200 µL dH2O and 2 µL of 2% bromophenol blue was added to 
serve as a mixing aid. Then the solution was dropped onto 12 grams of bacon 
flavored transgenic dough (BioServ #S3472) and mixed with a spatula until no 
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blue streaks remained. The dough was pressed into a 100 mg pill molds and left 
to dry for two days (119). Stock solutions of (R)-Ketorolac (Lot # 2-KMT-132-2), 
and (S)-Ketorolac (Lot # 2-KMT-129-2) (Toronto Research Chemicals Inc.) were 
made by adding 1 mL of 100% methanol directly to the 5 mg of powdered drug in 
each vial. To make 100 pills, 440 µL of the stock solution was combined with 
bromophenol blue, added to dough, mixed and put into pill molds, as described 
before.  
3.2.2 Mice  
FVB/N-Tg(MMTV-PyVT)634Mul/J mice, hereafter referred to as MMTV-
PyMT mice were originally obtained from The Jackson Laboratory. The female 
mice used are heterozygotes bred by crossing a MMTV-PyMT male to a wild 
type FVB female resulting in approximately half the offspring being transgenic 
(MMTV-PyMT positive). Animals were housed at the animal research facility at 
the University of New Mexico Health Sciences Center. They were maintained 
under a controlled temperature of 22–23°C with a 12hr light, 12hr dark cycle and 
fed normal chow ad libitum. All procedures were approved by the University of 
New Mexico Institutional Animal Care and Use Committee and carried out in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
Animal studies were conducted under an approved protocol 14-101235-HSC. 
3.2.3 Experimental Design and Dosing Schedule  
Three cohorts of mice were used for this study. At five or six weeks of age, 
MMTV-PyMT female transgenic mice were housed into treatment groups of 2-3 
mice per cage and trained to eat pills by being offered placebo pills twice a day 
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for three days. An oral route of dosing was chosen to most accurately reflect the 
kind of drug administration a patient might experience. Standard clinical ketorolac 
dosing includes one initial IV or IM dose and then, if continued, oral dosing (42). 
The pill method of dosing was chosen over oral gavage to decrease the amount 
of stress to which the animals were subjected (119). 
After the training period, mice were dosed with 1 mg/kg of correlating drug 
or placebo every 12 hours for the duration of the study (119). At varying intervals, 
mice were sedated with isofluorane, weighed and palpated for tumor growth. No 
tumor became externally visible.  
This study included 38 mice. At least one mouse was dropped from the 
final data sets due to refusal to consume the pill. Mice were housed into one of 
four treatment groups: placebo, racemic ketorolac, (R)-ketorolac, or (S)-ketorolac 
and dosed every 12 hours for 20 days. On day 20 of dosing (8 weeks old), mice 
were sacrificed and organs and tissue were harvested and preserved.  
3.2.4 Dissection  
Mice were euthanized, two at a time, by injecting 200 µL of Sleepaway 
into the peritoneal cavity. After death was confirmed, they were weighed and 
then doused with 70% EtOH. Cardiac punctures were performed using heparin 
coated needles and stored in heparin tubes. Blood was stored in epitubes on ice 
until it could be separated by centrifuging at 2500 rpm for 10 minutes. Serum was 
stored at -80⁰C. Clamping forceps were used to clamp off the right lung which 
was then cut out and snap frozen in liquid nitrogen. A probe was used to lift the 
trachea and cut a small slit into which a small blunted needle was inserted and 
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4% paraformaldehyde (PFA) was injected to gently inflate the left lung. The 
trachea was clamped off with locking forceps and the lung was separated from 
the body and kept in 4% PFA at 4⁰C. The stomach was removed, slit open and 
cleaned out with PBS, and kept in 4% PFA. One kidney from each mouse was 
removed, weighed, bisected sagittally and fixed in 4% PFA. Sizeable mammary 
tumors were removed and snap frozen in liquid nitrogen. Skin bands around the 
4th mammary glands were removed and pinned to a tray which was then flooded 
with 4% PFA. The next day the mammary glands were removed from the skin 
and placed in embedding cassettes in PBS for processing. Axillary and inguinal 
lymph nodes and a piece of liver were removed and put into epitubes with 4% 
PFA. Unless otherwise noted, all tissue preserved in 4% PFA was later moved 
into 50% EtOH or paraffin embedded for permanent storage.  
3.2.5 Mammary Tissue Whole Mounts  
Mammary glands were isolated from mice in the 21 day study. Mammary 
glands stored in 4% PFA underwent two changes of acetone over 8-24 hours 
and then were changed to water for 1 hour. Carmine alum stain (made by 
combining 1 g carmine, 2.5 g aluminum potassium sulfate and 450 mL dH2O, 
boiling for 20 minutes and adjusting the volume to 500 mL with dH2O and 
filtering) was used to stain the mammary glands overnight. The mammary glands 
were sequentially changed into water, 70%, 85%, 95%, 100% and 100% EtOH 
for one hour each, then left in HemoDE (Electron Microscopy Sciences, Hatfield, 
PA) overnight. Mammary glands were kept in individual vials in methyl salicylate 
(Wintergreen) (Sigma-Aldrich, St.Louis, MO). Whole mounts were imaged with 
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MoticCam 2300 running Motic software on an Olympus SZH dissection 
microscope. Pixel intensity of tumor and non-tumor areas was analyzed using 
ImageJ software. 
3.2.7 Lung Preservation  
Left lungs, previously inflated with 4% PFA, were rinsed twice in PBS and 
embedded in paraffin. Cassettes containing tissue were immersed in 50%, 70%, 
70%, 80%, 95%, 100%, and 100% EtOH, HemoDE twice, and paraffin twice for 
one hour each. Tissue was embedded in paraffin blocks and, 3-10 µm sections, 
100 µm apart were placed on slides, and stained with hematoxylin and eosin 
(H&E).  
3.2.8 Tissue Preservation  
Tumor, kidney, liver, and lymph node tissue preserved in 4% PFA 
overnight was moved into 50% EtOH for permanent storage or was rinsed three 
times in PBS for at least 30 minutes each time and embedded in paraffin. 
Cassettes containing tissue were immersed in 50%, 70%, 70%, 80%, 95%, 
100%, and 100% EtOH, HemoDE twice, and paraffin twice for one hour each. 
Tissue was embedded in paraffin blocks and kept at room temperature. 
3.2.9 (S)-Ketorolac Mouse Study  
Three mice were used in this study to examine the conversion of (S)-
ketorolac to (R)-ketorolac. At the beginning of 6 weeks of age, these mice were 
trained for three days to eat a placebo pill as described before (119). They were 
then fed a pill containing 1 mg/kg of (S)-ketorolac every 12 hours, 5 days a week, 
for 7 days. Mice were sacrificed using CO2 gas, and cardiac punctures were 
61 
 
performed. Blood samples were placed into plain epitubes. Samples were 
centrifuged at 2500 rpm for 10 minutes, separated into serum and red blood cells 
and stored at -80⁰C, until HPLC could be performed. 
3.3 Results - 21 day studies  
3.3.1 Weekly and Final Weights 
To investigate the effects of ketorolac on tumor growth and to analyze the 
potential toxic effects of the drug mice were treated with 1 mg/kg of ketorolac or 
its enantiomers for 21 days. Over the course of the study, mice were weighed as 
an indicator of positive health and growth. One mouse in the racemic ketorolac 
treatment group was found to have malocclusions and was ultimately dropped 
from the study. When the data was normalized the placebo treated mice gained 
significantly more weight than the R-ketorolac and S-ketorolac treated mice, but 
not the racemic ketorolac treated mice. These differences may be attributed to 
differences between litters, as the mice were not randomly chosen from different 
litters for each treatment group. In later experiments, mice from each litter were 
more evenly distributed amongst treatment groups. One cohort of mice were 
dropped from the weight gain data but included in the final mass data because 
their mass was recorded on different days than the other cohorts. Statistical 
analysis was conducted using a two-way ANOVA with a Bonferroni post-test. 
There were no significant differences in the final mouse mass between treatment 
groups. Final mouse weights were recorded at the time of sacrifice at 8 weeks of 
age. All of the mice had a final mass of around 20 grams. No significant 
differences were observed between treatment groups.  
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Figure 3.3 Short Term Study Mouse Mass 
Mouse weights were recorded routinely over the course of the study and final 
mouse weights were recorded at the end of the study. The study was concluded 
after 21 days of treatment when the mice were about eight weeks old. In the 
normalized mouse weight gain, the R-ketorolac and S-ketorolac treated groups 
gained significantly less weight than the placebo treated group. Statistical 
analysis was conducted using a two-way ANOVA with a Bonferroni post-test. 
There were no significant differences in final un-normalized body mass between 
treatment groups (B). 
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3.3.2 Kidney Weights 
Renal toxicity is a primary concern associated with long term ketorolac 
treatment(42). Because of this concern, one kidney from each mouse was 
removed and weighed. All of the mouse kidneys had a mass of 0.093-0.16 
grams. The average kidney weight was 0.122 g for the placebo group, 0.13 for 
the racemic group, 0.132 for the (S)-ketorolac group and 0.126 for the (R)-
ketorolac group. There was no significant difference in mouse kidney weights 
between treatment groups.  
The kidney weight over total weight ratio was calculated for each 
treatment group and no significant differences were seen between treatment 
groups. All of the mice had a kidney weight to total weight ratio of about 0.006.  
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Figure 3.4 Short Term Study Kidney Weights 
At the time of dissection, kidney weight was recorded as an assessment of 
kidney toxicity of ketorolac. There was no significant change between treatment 
groups when compared to placebo controls either in total kidney weight (A) or in 
the kidney weight versus total weight ratio. 
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3.3.3 Short Term Study Weekly Palpable Tumor Load 
Tumor growth was monitored by routine palpations over the course of the 
study. The overall number of palpable tumors increased with age and over the 
course of treatment in mice. No immediately discernable differences were 
observed between treatment groups. It is important to note that the number of 
tumors that could be felt by palpation from week to week is subjective and not an 
exact indicator of tumor growth.  
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Figure 3.5 Short Term Study Weekly Palpable Tumor Load  
Over the course of the study, mouse mammary glands were palpated for 
presence of tumor growth. The amount of tumors detected increased over time 
but the difference between groups was not significant. 
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3.3.4 Whole mounts of mammary glands 
The mammary tumors did not grow large enough to separate from the 
mammary gland for weighing so instead, the fourth mammary glands were 
removed and imaged as whole mounts. Whole mounts of carmine stained 
mammary glands were imaged on a dissection microscope. The figure below is 
representative of a typical mammary gland. Most mammary glands in the 8-week 
old PyMT mouse had an area of denser tumor tissue in the proximal area of the 
gland which gradually decreased in amount and density moving distally through 
the gland. If not obscured by tumor tissue, the lymph node can be observed as a 
distinctly darker oval area slightly more proximal from the center of the gland. 
The mammary ducts spread out from the proximal end of the mammary gland, 
normally ending in slightly rounded terminal end buds. Mammary gland 
structures are surrounded by a combination of fatty tissue, and connective tissue 
which stains a slightly darker color than the fatty tissue but not as dark as tumor 
tissue.  
Whole mount mammary gland images are representative of a range of 
mouse mammary gland morphologies observed. In the mammary gland from the 
placebo treated mouse the darker areas of tissue are tumorigenic and are spread 
throughout the gland. In the mammary gland from a (R)-ketorolac treated mouse 
some tumors are visible, but they are fewer in number and size than in the 
placebo treated mammary gland.  
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Figure 3.6 Mammary Gland Whole Mount Example 
In the carmine stained whole mount mammary gland from an 8 week old MMTV-
PyMT mouse, tumor tissue can be observed as well as the lymph node, fatty 
tissue and terminal end buds of the ductal network. This is a typical 
representative image.  
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Figure 3.7 Treated vs. Untreated Mammary Gland Whole Mounts 
Mammary glands from (R)-ketorolac treated mice had less tumor growth and 
more areas with fatty tissue and clearly delineated terminal end buds than 
mammary glands from placebo treated mice.  
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3.3.5 Histograms of Whole Mounts 
 Using ImageJ, pixel intensity information was collected from each 
mammary gland whole mount and compiled into histograms. ImageJ assigned 
numbers 0 through 255 to indicate the intensity of pixel color ranging from white 
to black, then counted how many pixels fit into each category of pixel intensity. 
The left and right mammary glands from each mouse were analyzed and 
averaged into one set of pixel data for each mouse. Pixel counts for each 
treatment group were compiled into linear histograms  
In the whole mount image, the lighter pixels (pixels in the lower range) are 
non-tumorigenic tissue, while the darker pixels (pixels in the higher range) are 
tumorigenic tissue. Additionally, the drawing tool was used to exclude the lymph 
node and include only tissue up to the terminal end buds before analyzing the 
image. The resulting histograms showed peaks in pixel counts in the darker 
spectrum of pixels, representing a delineation between normal tissue and 
tumorigenic tissue.  
Pixels that were dark enough to be considered tumor areas generally fell 
into the 175-225 range. Comparison of histograms for each treatment group 
show significant differences between the treatment groups and the placebo 
groups of mice. Mice in the placebo group had significantly higher amounts of 
tumorigenic lesions in their mammary glands than either the racemic ketorolac, 
(S)-ketorolac, or (R)-ketorolac treatment groups. Each group had an n of 9 and a 
p value less than 0.0001. Significance was determined using the student’s 
unpaired t-test.  
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Figure 3.8 Mammary Gland Whole Mount Histograms 
Darker pixels indicated more tumorigenic tissue while lighter pixels indicated 
areas with more fatty tissue. Placebo treated mice had significantly greater 
density of tumor tissue in their mammary glands than the racemic or 
enantiomeric ketorolac treated groups. There was no significant difference in 
tumor density between the ketorolac treated groups. Significance was 
determined using the student’s unpaired t-test. 
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3.3.6 Lung H&E Staining 
In this study it was hypothesized that ketorolac treatment would decrease 
the occurrence of mammary gland tumors metastasizing to the lung. Lung tissue 
was collected and analyzed for the presence of metastasis. H&E stained lung 
tissue in mice at eight weeks of age showed no tumor metastasis. There were no 
differences in lung tissue appearance between placebo and ketorolac treated 
mice. The lung tissue observed appeared to be visually normal healthy mouse 
lung tissue. 
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Figure 3.9 H&E Stained Lung Tissue 
Mouse lungs were inflated with 4% PFA and paraffin embedded. Lung tissue was 
sliced in 3-10 µm sections and H&E stained. At eight weeks of age, no difference 
in lung tissue could be discerned between placebo and ketorolac treated mice, 
and no metastasis was detected. The image shown is a representative sample. 
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3.4 Discussion 
This 21 day study was conducted to provide information about the early 
effects of ketorolac treatment, to determine toxicity, and to examine differences, 
or lack thereof, between treatment groups helping to set standard protocols for a 
longer study.  
Mouse mass was routinely recorded as an indicator of drug toxicity and 
overall mouse health. When the data was normalized, by normalizing each 
mouse’s weight to its starting weight, the placebo treated mice weighed 
significantly more than the R-ketorolac and S-ketorolac treated mice, but not the 
racemic treated mice. This difference may have been caused by the individual 
attributes of each litter of mice that were used, as the mice from each litter were 
not evenly distributed amongst all the treatment groups. In future experiments, 
mice from the same litter were even distributed between treatment groups. Final 
un-normalized mouse weights were not significantly different, indicating that 
ketorolac has little toxic effects on the mouse’s ability to gain weight normally. 
A second indicator of drug toxicity, kidney mass and kidney mass to total 
body mass ratios, showed no significant differences between treatments or when 
compared to placebo treated mice. These results suggest that ketorolac is not 
highly toxic when used for 21 days. 
Whole mount images of the short term study mammary glands were 
imaged and assessed for tumor density. The mice were 8 weeks old at the time 
of sacrifice. This is the age at which the mammary glands begin growing tumors. 
Due to this timing, we were able to see a delay or decrease in tumor growth as a 
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result of ketorolac treatment that is not as easily observed as the disease 
progresses. The extent and distribution of tumor growth and burden in the 
placebo treated mice was typical for their age. Visually, there was less tumor 
burden in ketorolac treated mice than in placebo treated mice. Histograms 
describing tumor growth in the mammary gland whole mount images indeed 
showed a significant decrease in tumor burden in the ketorolac treated mice, 
when compared to placebo treated mice. The significant decrease in tumors was 
present in racemic, (S)-, and (R)-ketorolac treated groups. Keeping in mind the 
ability of mice to interconvert (S)-ketorolac to (R)-ketorolac, these results are 
logically sound.  
Lung tissue was assessed for metastatic lesions, but as the mice were still 
very young and metastasis is not generally observed in MMTV-PyMT mice until 
at least 12 weeks of age, no metastasis was present (33,106). The short term 
study mouse lungs were visually normal and healthy.  
In this shorter treatment duration, therapeutic concentrations of ketorolac 
did not cause toxic effects in MMTV-PyMT breast cancer mouse models. The 
mice remained healthy looking and did not suffer any measurable toxic effects 
from the treatment. Ketorolac treatment significantly decreased the amount of 
mammary gland hyperplasia. The results observed with racemic ketorolac and its 
enantiomers did not vary significantly. As a result, in further experiments, (R)-
ketorolac treatment only, was conducted. 
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4. THE EFFECTS OF KETOROLAC ON PROLIFERATION AND 
METASTASIS OF MAMMARY GLAND TUMOR CELLS IN PYMT MICE 
4.1 Introduction 
 Metastasis is the main cause of death in breast cancer patients (120). 
Human breast cancer most often metastasizes to the lung, liver, bones and brain 
(121). Two mouse breeds commonly used to model human breast cancer and 
metastasis are MMTV-HER2/neu/ErbB2 (hereafter MMTV-HER2) and MMTV-
PyMT mice. MMTV-HER2 mice overexpress HER2, leading to the development 
of multifocal adenocarcinomas and lung metastasis lesions 15 weeks after 
pregnancy (122). In humans, HER2 gene overexpression is found in 15-30% of 
all breast cancers and contributes to mammary tumor formation (10). HER2 is an 
EGF family-type receptor tyrosine kinase, which regulates cell growth, 
differentiation and cell survival by activating proteins involved in signaling 
pathways such as MAPK, and PI3K/Akt pathways (reviewed (11)). HER2 
overexpression specifically induces tumor formation and progression through the 
GEF protein, Tiam1 (105).  
The MMTV-HER2 mouse tumor formation has a longer latency than in 
MMTV-PyMT mice, and only occurs after pregnancy (107). Like MMTV-HER2 
mice, MMTV-PyMT mice overexpress HER2 resulting in the constitutive 
activation of cell growth, differentiation and cell survival signaling pathways. Also, 
tumor formation in MMTV-PyMT mice occurs independently of pregnancy with a 
shorter latency (107). The propensity for lung metastasis in MMTV-PyMT mice, 
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and their similarities to human breast cancer, makes them a good model for 
studying potential anti-metastatic compounds such as (R)-ketorolac.   
This study focused on (R)-ketorolac treatments compared to placebo 
treatments, and the ability of (R)-ketorolac to prevent lung metastasis. Tumor 
growth in relation to treatment was documented and lung tissue samples were 
collected to measure metastasis. We hypothesized that (R)-ketorolac would 
inhibit the metastatic ability of mammary gland tumor cells resulting in fewer 
metastatic lesions in the lungs of (R)-ketorolac mice when compared to placebo 
treated mice.  
4.2 Materials and Methods 
4.2.1 Experimental Design and Dosing Schedule  
Pills were prepared as described previously. Five cohorts of mice were 
used total. Three cohorts were sacrificed at 12 weeks of age and two cohorts 
were sacrificed at 14 weeks of age. The 12 and 14 week experimental data is 
combined in the results where appropriate. The experiment proceeded much as 
described previously with the following changes: Mice were dosed twice a day, 
12 hours apart, 5 days a week. On the day of dissection, mice did not receive 
their morning dose. Once a week mice were sedated with isofluorane, weighed 
and palpated for tumor growth. Externally visible tumors were measured using 
calipers and an approximate volume was calculated using the formula: volume = 
length*width*(π/4).  
This study included 24 mice in the 12 week group, and 13 mice in the 14 
week group. Two mice were dropped from the 12 week study, and 3 mice were 
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dropped from the 14 week study. Mice were housed into one of two treatment 
groups: placebo, or (R)-ketorolac, and dosed until the age of 12 weeks and 5 
days or 14 weeks and 1 day. The limiting age of mice for the time of sacrifice in 
the first, 12 week study, was determined when one individual within the first 
group of mice grew a tumor that exceeded the maximum 15 mm diameter limit 
set by University of New Mexico’s Institutional Animal Care and Use Committee 
(IACUC) guidelines. This end date decision put the mice between 48 and 51 
days of treatment at the time of sacrifice. On day 48-51 of dosing (12 weeks, 5 
days old), mice were sacrificed and organs and tissue were harvested and 
preserved. Further cohorts of mice were treated until 14 weeks of age as there 
were not enough metastatic lesions in the lungs of the 12 week old mice to make 
any conclusions about lung metastasis. Data from the 14 week old mouse cohort 
was combined with the weight change and palpable tumor load data of the 12 
week old mice to increase the n but tumor weight and lung metastasis data was 
reported separately due to the age, and thus tumor progression difference, at 
time of sacrifice. 
4.2.2 Dissection  
Mice were euthanized by injecting ~100 µL Phenobarbital (Fatal Plus 
59mg/mL, 0.1 mL/25 g mouse) into the peritoneal cavity. Mice were weighed and 
then doused with 70% EtOH, as previously described. Cardiac punctures were 
performed with plain non-coated needles and blood was put into plain 1.5 mL 
epitubes and stored on ice until it could be separated by centrifuging at 2500 rpm 
for 10 minutes. Serum was stored at -80⁰C. Tumors from all 10 mammary glands 
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were removed, photographed, weighed and cut in half. Half the tumor was snap 
frozen in liquid nitrogen and half was preserved in 4% PFA until it could be 
paraffin embedded. Lung, stomach, kidney and liver collection and storage were 
performed as previously described.  
4.2.3 H&E Mammary Tumor Staining 
 Mammary gland tumors were fixed in 4% PFA, then paraffin embedded. 
Sample sectioning, H&E staining, and analysis was conducted by Donna 
Kusewitt, DVM, PhD, ACVP. 
4.2.4 RNA Isolation and qRT-PCR  
Lung and mammary tumor tissue samples from the 81 day studies were 
weighed into 30 mg samples and put into 1.5 mL epitubes. Liquid nitrogen was 
added to the epitubes to freeze tissue. 300 µL of RLT buffer, from an RNeasy 
Mini Kit (Qiagen, Valencia, CA) was added to the sample and an electric hand 
drill fitted with nuclease-free 1.5 mL pestles (Kimble-Chase, Vineland, New 
Jersey) was used to break down the tissue. The lysate was homogenized using 
the QIAshredder (Qiagen, Valencia, CA) and RNA was isolated using the 
RNeasy Mini Kit according to the manufacturer’s protocol. RNA was converted 
into cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Inc. Foster City, CA) and a TC-3000X Thermocycler (Techne Inc., 
Burlington, NJ). cDNA was generated from 1000 ng of RNA of each sample. The 
resulting cDNA samples were diluted 1:3 with nuclease-free water.  
Quantitative Real-Time polymerase chain reaction (qRT-PCR) was 
conducted using six mouse primers: Rac1, Rac1b, RhoA, Cdc42, PyMT and β-
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actin (Qiagen, Valencia, CA; excluding PyMT, catalog numbers QT01070146, 
QT00127673, QT00197568, QT00091560, QT00095242 respectively). PyMT 
primers used were, PyMT forward: 5’-CGG CGG AGC GAG GAA CTG AGG 
AGA G-3’ and reverse: 5’ TCA GAA GAC TCG GCA GTC TTA-3’ (33). Fast 
SYBR® Green Master Mix (Applied Biosystems, Inc. Foster City, CA) was used 
to make a 1:5 master mix for each primer. Samples were loaded in triplicate in 
384-well plates using 6 µL of master mix and 4 µL of sample per well. A 
nuclease-free water sample was used as a negative control, and β-actin was 
included as a positive control. Genes were amplified on a 7900 HT Fast Real-
Time PCR System (Applied Biosystems, Inc. Foster City, CA). Relative 
expression was calculated with the ΔΔct method, using β-actin as the normalizer 
and analyzing the treated samples in reference to placebo samples. 
4.3 Results - 81 Day Studies  
4.3.1 Weekly and Final Weights 
Mice were weighed on a weekly basis. In the 12 week study, at ages 9, 
10, 11 and 12 weeks, the placebo treated mice had a significantly greater overall 
body mass than the (R)-ketorolac treated mice, but this significance disappeared 
when the data was normalized. Each mouse’s weight was normalized to it’s 
starting weight to reflect relative change in mass. In the 14 week studies, there 
were no significant differences in body mass between treatment groups. Mouse 
body mass at four weeks old ranged from 15-20 grams across both treatment 
groups. Final mouse body mass for the mice sacrificed at 12 weeks of age was 
between 24.2-29.5 grams in the placebo group and 22-26.3 grams in the (R)-
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ketorolac group. The placebo group and (R)-ketorolac group had an n=11. Final 
mouse body mass for the mice sacrificed at 14 weeks of age was between 27.2-
32.7 grams in the placebo group and 24.2-34.0 grams in the (R)-ketorolac group. 
The placebo group for the 14 week treated mice had an n=6 while the R-
ketorolac group had an n=7. Three mice were dropped from the study in the 14 
week old mouse group. Two mice had malocclusions and were much smaller 
than other mice in the study, and one mouse was much larger than all other mice 
in the study. Significance was determined using an unpaired student’s t-test. 
Final mouse body weights were significantly different at 12 weeks but not 
at 14 weeks. At 12 weeks, placebo treated mice had a greater average body 
mass than (R)-ketorolac treated mice. Placebo treated mice had an average 
mass of 26.5 grams while (R)-ketorolac mice had a final average mass of 25 
grams. Significance was determined using an unpaired student’s t-test and 
yielded a p < 0.05. At 14 weeks there was no significant difference in mouse 
body mass, although there were only 5 mice in each treatment group. So, the 
small n is likely to be the reason for no significant difference. 
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Figure 4.1 Long Term Study Weekly Weight Gain and Final Weight 
Mouse mass was measured and recorded weekly. There was no significant 
difference in weight gain between the two treatment groups over the course of 
the study. When only the 12 week final mass was considered, there was a 
significant difference between the placebo and (R)-ketorolac treated groups (B). 
In the 14 week old mice, there was no significant difference in mass between 
treatment groups (D). Significance was determined using an unpaired student’s t-
test (B, D).   
83 
 
4.3.2 Kidney Weights 
There was no significant difference in the kidney weights between the 
placebo and (R)-ketorolac treatment groups in either age group. At 12 weeks the 
average kidney weight was 0.126 grams in the placebo group and 0.125 grams 
for the (R)-ketorolac group. At 14 weeks the average kidney weight was 0.135 
grams in the placebo group and 0.14 grams for the (R)-ketorolac group. 
Additionally, there was no significant difference between the two treatment 
groups when comparing the kidney weight to total weight ratios.  One mouse was 
excluded from the 12 week group when calculating kidney weight:total weight 
ratio because its end mass was an outlier due to very large tumors. The kidney 
mass in this particular mouse was comparable with the other mouse kidneys. 
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Figure 4.2 Long Term Study Kidney Weights 
Kidney weight and total weight ratios were calculated. There was no significant 
difference in kidney weight:total weight ratios between placebo and (R)-ketorolac 
treated groups (A). There was no significant difference in kidney weights 
between treatment groups in either the 12 week or the 14 week mice (B, C).  
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4.3.4 Weekly Tumor Growth 
The number of palpable tumors increased over the course of the 
experiment and with increasing mouse age. While the placebo group had slightly 
more palpable tumor growth than the (R)-ketorolac treatment group over much of 
the study, the difference was not significant. Additionally, palpation is a subjective 
measurement that varies from session to session and cannot be considered an 
exact indicator of tumor growth. 
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Figure 4.3 Long Term Study Weekly Palpable Tumor Load 
Throughout the course of the study, mouse mammary glands were palpated, and 
tumor growth was recorded weekly. Palpable tumors increased over the course 
of the study in placebo and (R)-ketorolac treated groups. Shown are the 
combined 12 and 14 week mouse experiments (A), 12 week only (B) and 14 
week only (C). There was no significant difference between treatment groups in 
the number of tumors felt.  
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4.3.5 Tumor Mass 
Mammary tumors grew large enough to completely encompass each 
mammary gland and were impossible to separate from the mammary glands. 
The mass of each mammary gland/tumor was recorded. To compile the tumor 
mass to total mass ratio, the total tumor mass was summed for each mouse and 
compared to total mouse weight. A difference in tumor weight, while slightly 
greater in the placebo treated mice, was not significant between treatment 
groups. The tumor weight to total weight ratio was slightly greater in the placebo 
treated mice, but not significant. At 12 weeks, the average tumor weight in the 
placebo group was 3.4 grams and in the (R)-ketorolac group was 2.7 grams. At 
14 weeks, the average tumor weight in the placebo group was 5.2 grams and in 
the (R)-ketorolac group was 5.5 grams. One mouse was excluded from the (R)-
ketorolac group because abnormally large tumors caused it to be an outlier. 
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Figure 4.4 Long Term Study Tumor Weights 
The tumor mass total:mouse mass ratio was calculated. There were no 
significant differences between the two treatment groups (A). The total tumor 
mass from each mouse was recorded and found to not be significantly different 
between placebo and (R)-ketorolac treated mice. 14 week old mice had greater 
total tumor mass than 12 week old mice (B, C).   
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4.3.6 H&E Mammary Tumor Staining 
 H&E mammary tumor staining was conducted by Donna Kusewitt, DVM, 
PhD, ACVP, on 12 week old mouse mammary gland tumors. There was no 
significant difference in the average number of lesions per mouse. There were 
fewer mice in the (R)-ketorolac treated group than the placebo control group 
affected by early adenoma (Ad) and early carcinoma (Ca) suggesting that (R)-
ketorolac may help to inhibit early cancer cell proliferation, but the results were 
not significantly different. 
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Figure 4.5 H&E Staining of Mouse Mammary Tumors Show No Change 
Mouse mammary tumors were stained and analyzed for the presence of cell 
proliferation. There were no statistically significant differences in the average 
number of lesions present between the (R)-ketorolac treated mice and the 
placebo control (A). There was a suggestion of a delayed early tumor 
progression in the (R)-ketorolac treated mice when the percent of mice affected 
was analyzed, but the differences were not significant (B). 
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4.3.7 Lung H&E Staining 
H&E stained lung tissue sections were scanned for presence of tumor 
metastasis. Normal lung tissue had a lacy appearance with pink stained blood 
vessels throughout. Red blood cells left behind also stained pink. Areas of 
metastasis were defined as 10 or more purple stained nuclei grouped together in 
a disorganized arrangement.  
ImageJ was used to outline the areas of metastasis and measure the total 
number of pixels within the outlined area per mouse. The total number of 
metastasis sites per mouse were also counted. There was no significant 
difference in the amount of lung metastasis between the (R)-ketorolac treatment 
group and the placebo group in the 12 week old mice. In the 12 week old placebo 
treated mice 8 out of 11 mice had less than 5 detectable metastatic sites, and in 
the (R)-ketorolac treated mice 8 out of 9 mice had less than 5 detectable 
metastatic sites. So, a longer study was conducted to increase the chances of 
the presence of lung metastasis. In the 14 week old mice there was a slight 
increase in the metastatic area and a slight increase in the total number of 
metastatic sites in the placebo treated mice, when compared to the R-ketorolac 
treated mice, but the increase was not significant. It is important to note, as of 
this writing, the 14 week studies are not yet complete and thus, the population 
size is still small. A greater population size may result in significant findings.  
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Figure 4.6 12 week old H&E Stained Lung Tissue 
Mouse lungs were inflated with 4% PFA and paraffin embedded. Lung tissue was 
sliced in 3-10 µm sections and H&E stained. Typical metastatic lung tissue is 
represented by image A. Metastasis in lung tissue was identified and quantified 
by using ImageJ to quantify the total number of metastasis foci (B) and the total 
number of pixels in each metastatic area (C). There was no significant difference 
in the amount of metastasis quantified in placebo and (R)-ketorolac treated mice, 
at 12 weeks of age. 
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Figure 4.7 14 Week Old H&E Stained Lung Tissue 
Metastasis in lung tissue was identified and quantified by using ImageJ. The 
number of metastasis foci (A), and the total number of pixels in each metastatic 
area (B) per mouse, were measured. There was a slight increase in the area and 
number of metastatic sites in the placebo treated mice when compared to the R-
ketorolac treated mice, but the differences were not significant. 
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4.3.8 qRT-PCR – 12 Weeks 
 qRT-PCR was used to assess gene expression of Rho-GTPases, Rac1, 
Rac1b, RhoA and Cdc42, and the mouse mammary tumor gene of interest, 
PyMT. All results were corrected using β-actin controls then normalized to their 
respective placebo control. A relative expression value of one, indicated no 
change from the placebo control. In the tumor tissue, there was no change in 
gene expression when comparing the treatment groups with the placebo control. 
In the lung tissue of (R)-ketorolac treated mice, there were slight upregulations of 
Rac1b and Cdc42 gene expression when compared to their respective placebo 
controls but the differences were not statistically significant. There was a small 
upregulation of PyMT gene expression in placebo controls when compared to the 
(R)-ketorolac treated control, which is the change we were expecting to see in 
the lung tissue of these animal models, but the change was not statistically 
significant.  
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Figure 4.8 qPCR in Tumor Tissue – 12 Weeks 
Gene expression levels in the tumors of (R)-ketorolac treated mice were not 
different from the placebo control treated mice. In both treatment groups the 
gene expression of Rac1 (A), Rac1b (B), RhoA (C), Cdc42 (D) and PyMT (E) 
were the same.   
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Figure 4.9 qPCR in Lung Tissue – 12 Weeks 
Gene expression of Rac1b (B) and Cdc42 (D) was upregulated in the (R)-
ketorolac treated mice but the difference was not significant. PyMT gene 
expression in the lungs of placebo treated mice and (R)-ketorolac treated mice 
was not significantly different (E). Gene expression of Rac1 (A), and RhoA (C) 
was not changed.   
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4.4 Discussion 
This 81 day study was conducted to examine long term effects of 
ketorolac treatment on tumor growth and metastasis as well as long-term toxicity 
studies. In humans, racemic ketorolac is not recommended for use longer than 5 
days duration due to adverse toxic effects (42). These longer studies were 
terminated earlier than the projected 81 days, due to a limiting factor of tumor 
growth exceeding 15 mm in length according to IACUC guidelines. The first set 
of long term experiments were terminated at 12 weeks because one mouse 
exceeded the tumor growth limits. However, that particular mouse was ultimately 
dropped from the study. A second, and now ongoing, set of experiments is being 
conducted to 14 weeks because no lung metastasis was observed in the 12 
week old mice and the majority of mice were within ethical animal treatment 
limits, as set by IACUC. According to other studies conducted, the MMTV-PyMT 
mice in this study are expected to have significant lung metastasis between 12 
and 14 weeks of age (33,106). It has been suggested that this particular line of 
MMTV-PyMT mice may have genetically drifted, resulting in tumor metastasis at 
a later age. These mice require a longer time for tumor and metastasis 
development. (see appendix for metastasis development) 
MMTV-PyMT mouse models in this study developed palpable tumors 
around 8 weeks of age and caliper measurable tumors around 10 weeks of age. 
In the 12 week studies, there was a small increase in the number of palpable 
tumors in the placebo treated group when compared to the (R)-ketorolac treated 
group, but the difference was not significant and may have been attributed to 
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biased observation as the palpations were not conducted blindly. Overall, the 
number of palpable tumors increased with age, however the number of tumors 
felt is very subjective and difficult to accurately quantify from week to week. 
Additionally, external measurement of tumor volume could only be estimated 
because not all tumors were perfectly spherical. Some tumors grew oblong and 
flattened while other tumors, particularly the 2nd and 3rd mammary gland tumors, 
and later the 4th and 5th mammary gland tumors, began to grow into a single 
mass as they became larger. 
In this study a significant difference final in mouse mass was observed in 
the 12 week study, but not in the 14 week study. When the rate of weight gain 
was normalized, there was no significant difference in weight between the two 
treatment groups. The differences at 12 weeks could be attributed to more than 
one reason. When overall tumor mass was measured in the longer term study, 
the placebo mice had a greater overall tumor mass and a greater tumor:body 
mass ratio, however the differences were not significant. The placebo treated 
mice may have had a greater mass due to their increased tumor burden. On the 
other hand, the (R)-ketorolac treated mice may have exhibited decreased growth 
due to toxic effects of the drug. Considering the lack of other toxicity indicators, 
i.e. kidney mass differences, the former explanation is more likely to be true. The 
differences in mouse mass between treatment groups at 14 weeks of age were 
not significant. This could be an indication that the (R)-ketorolac treated mouse 
tumors were delayed in growth and not contributing to overall mass until that time 
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point. It also may be due to the small number of mice in the 14 week study. A 
larger population may change these final results.  
In the long term studies, the mammary tumor growth was so extensive, 
separation of mammary gland and tumor was deemed impossible and instead 
whole tumor/mammary gland sections were removed for analysis. Tumor weight 
totals per mouse were recorded and compared as whole numbers and as a ratio 
of tumor weight to total mouse weight. There was no significant difference in 
tumor weight totals in either the 12 week or the 14 week old mice. Although, the 
14 week old mice had a greater overall tumor weight than the 12 week old mice, 
which was expected. There was also no significant difference in the tumor 
weight:total weight ratios between the two treatment groups. These results 
indicate that (R)-ketorolac is not affecting the overall tumor growth.  
Lung tissue was assessed for metastatic lesions. Between 12 and 14 
weeks of age, the MMTV-PyMT mouse model exhibits mammary tumor 
metastasis to the lungs (33,106). In the 12 week old mouse population, some 
mice had obvious metastatic lesions, while some had possible small initial sites 
that were difficult to identify, and still others exhibited no lung metastasis at all. 
There was no trend observed between the presence of metastatic sites and 
treatment groups. A longer study treating MMTV-PyMT mice to 14 weeks of age 
is currently underway to allow adequate time for lung metastasis to develop. 
Preliminary results indicate that while there is more overall lung metastasis in the 
14 week old mice, the amount of metastasis is not as great as expected for this 
age of PyMT mouse. Studies of lung tissue collected months earlier, from the 
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same line of MMTV-PyMT mice have shown abundant lung metastasis as early 
as 13 weeks of age (see appendix). It is suspected there has been a genetic drift 
in the expected phenotype of this particular line of mice and it may be prudent to 
end this colony and purchase new breeding pairs, before continuing these 
experiments.   
Considering the lack of lung metastasis trend in the 12 week old mouse 
models, a difference in Rho-GTPase and PyMT gene expression was not 
expected between treatment groups. Nonetheless, PCR was conducted on both 
tumor samples and lung tissue samples from the study, to examine what 
changes, if any, were able to be observed in small Rho-GTPase and PyMT 
expression levels. There were no significant changes in gene expression in the 
tumor samples, most likely because both the (R)-ketorolac and placebo treated 
mice grew tumors at nearly the same rate and had tumors of similar sizes. In the 
lung tissue, there were small upregulations of Rac1b and Cdc42 gene expression 
in the (R)-ketorolac treated mice but the differences were not significant. It was 
expected that the (R)-ketorolac treated mice would exhibit less lung metastasis 
and thus less PyMT gene expression in the lungs than the placebo treated mice 
and while there was a noticeable trend, the difference was not significant. The 14 
week animal studies are expected to exhibit more significant changes in gene 
expression and solidify the trends observed.  
While the animal experiments did not yield complete results, we were able 
to observe interesting trends in ketorolac treated animal models. Therapeutic 
concentrations of ketorolac did not cause toxic effects in MMTV-PyMT breast 
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cancer mouse models. There was a trend in decreased PyMT expression in the 
lungs of mice treated with (R)-ketorolac, suggesting a decrease in tumor 
metastasis, but more work will have to be done to confirm these results. 
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5. SIGNIFICANCE AND FUTURE DIRECTIONS 
Cancer is often described as having specific hallmarks that distinguish it 
from other diseases, one of those being inflammation (123). It has been 
demonstrated that several NSAIDs, such as ketorolac, possess anti-cancer 
properties that may be useful as part of anti-cancer therapies (40). Racemic 
ketorolac is routinely used to reduce pain and inflammation in surgical cases. 
However, the (S)- form of ketorolac is primarily responsible for the drug’s anti-
inflammatory properties (48). (R)-ketorolac, previously believed to be relatively 
inert, has recently been shown to have an important role in decreasing tumor 
metastasis and thus increasing patient survival rates (45). Work performed in our 
research group has found that in ovarian cancer cells, (R)-ketorolac inhibits small 
Rho-GTPases, Rac1 and Cdc42 which are vital in enabling the cell to 
metastasize (50).  
This study demonstrated the ability of (R)-ketorolac to inhibit early breast 
tumor growth without causing significant toxic effects to surrounding cells, or the 
organism as a whole. The main concern with long term use of ketorolac is the 
drug’s toxic effects on the body, including gastrointestinal ulcerations and 
bleeding (42). These toxic effects can be attributed to the (S)- enantiomer of 
ketorolac which inhibits COX1/2, enzymes important in maintaining mucosal 
linings in the stomach and intestines (52). (R)-ketorolac, when used to treat cells 
in culture, was not cytotoxic at relatively high concentrations. It did not alter the 
viability of breast cancer cells, nor did it alter their cell cycle behavior. In mouse 
models, when (R)-ketorolac was used for durations longer than the clinically 
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recommended limit of five days, there were no immediate toxic effects. These 
results indicated that (R)- enantiomer of ketorolac alone may be considered safe 
for long term use.  
The in vitro experiments yielded many negative, but not necessarily 
inconclusive results. From these experiments, we found that (R)-ketorolac is a 
relatively benign drug, not decreasing cell viability or growth but inhibiting the 
cell’s ability to migrate and form colonies. We have not shown a direct interaction 
between (R)-ketorolac and Rac1 and Cdc42 in breast cancer cells, so further 
experiments are imperative to understanding (R)-ketorolac’s mechanism of 
action in breast cancer cells. Immunoblotting to examine the activity of Rac1 and 
Cdc42 in breast cancer cell lines when treated with (R)-ketorolac is one step that 
could be taken.  
The animal studies conducted had a few limitations that are important to 
note. The ability to give each mouse an exact dose of ketorolac every 12 hours 
was not feasible. The mice were given oral doses of ketorolac in the form of 
bacon flavored pills. Sometimes certain mice did not eat their pills, and as the 
study was not conducted by oral gavage, we could not force the mice to eat their 
pills if they refused. Careful notes were taken and mice that refused their pills the 
majority of the time were dropped from the study. The occasional missed dose 
was noted, but not considered an absolute reason to drop the mouse from the 
study. While not optimal, it is very likely that an actual human may occasionally 
forget to take their medication at the exact indicated time.  
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One complication that arose with the mouse studies was lack of 
knowledge of the exact duration of time necessary to run the experiment. While 
the literature indicates positive lung metastasis in MMTV-PyMT mice at 14 weeks 
of age, this particular group of MMTV-PyMT mice has been known in the past to 
have lung metastasis at 12-13 weeks old (33). However, there was a suspected 
genetic drift, because at 12 weeks old, there was little to no lung metastasis 
observed in the lung sections. Briefly, lung tissue samples from untreated PyMT 
mice in this same breeding group at 12, 13, 14, and 16 weeks of age were H&E 
stained and examined for metastasis. It was decided that 14 weeks would be the 
best age of sacrifice for examining lung metastasis. Currently, another study is 
being conducted, carrying out this experiment to 14 weeks, and some of that 
data has been included in the results. We hope to see a positive effect of (R)-
ketorolac treatment on lung metastasis.  
Future animal experiments could involve other known breast cancer 
mouse models such as a HER2 mouse models. It is important to ask the 
question: Does (R)-ketorolac treatment yield significant benefits in other breast 
cancer models? It would also be interesting to examine the effects of (R)-
ketorolac treatment on xenograft or allograft mouse models. Additionally, 
conducting longer term experiments, modeling a chronically medicated individual, 
could yield information about how long a patient may benefit from (R)-ketorolac 
treatment, and answer the questions: Is there a point where (R)-ketorolac 
treatment is no longer significantly beneficial? And is (R)-ketorolac treatment able 
to keep metastasis at bay, long term? Finally, because (R)-ketorolac has been 
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shown to have positive results in multiple cancer forms, including ovarian, colon 
and now breast cancer, testing its effectiveness on preventing metastasis of 
other forms of cancer could be a logical next step.  
What we know from these experiments, it is possible that the (R)-ketorolac 
enantiomers may be safely used for long term treatment in an effort to decrease 
breast cancer metastasis, although more evidence is needed. As FDA guidelines 
become stricter, it will be important to look at pre-approved drugs in new ways. 
Currently, much of the focus of cancer drug discovery is on creating new 
compounds that have toxic effects on cancer cells. While some of these 
compounds may be effective at killing cancer cells, they can often be so toxic 
that they could never be successfully used in vivo without causing serious 
damage or death. New drugs take approximately 10-15 years to advance from 
invention to routine clinical use and can cost millions of dollars during the course 
of development (124). Utilizing FDA approved drugs in off-label use against 
cancerous cells can improve cancer treatment options and decrease the time it 
takes for a therapeutic approach to move from the bench to clinical treatment. 
These experiments and other evidence in the literature suggest a benefit to 
administering even racemic ketorolac to cancer patients over other pain or anti-
inflammatory medications. A decrease in early breast cancer metastasis will lead 
to more positive patient outcomes, enabling patients to live a longer, better 
quality of life.  
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6. APPENDIX 
 
Figure 6.1 MMTV-PyMT Mouse Lung Metastasis Time Course 
MMTV-PyMT mice were sacrificed at increasing age time points and lung tissue 
was H&E stained and analyzed for presence and size of metastasis lesions. 
These mice were not given any drug treatments. At 12 weeks of age, almost no 
mice had lung metastasis. At 13 weeks of age the numbers of lung metastasis 
foci increased and remained around the same quantity at 16 weeks. This 
information helped us form the decision to repeat the long term (R)-ketorolac 
study to extend the sacrifice age to 14 weeks rather than 12 weeks. The total 
lung metastasis area increased around 13 weeks and remained around the same 
area at 16 weeks. There was a decrease in lung metastasis area at 14 weeks for 
this set of data, but there were only two data points at 14 weeks. There were no 
samples available for the 15 week time point.   
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